ProgressANNUAL REPORT 2008

The Michael J. Fox Foundation has ‘‘ managed to become, in its short life, the most credible voice on Parkinson’s research in the world. — The New York Times ’’

CONTENTS

2 LETTER FROM THE CEO, FOUNDER AND CO-FOUNDER

4 S CIENTIFIC PROGRESS REPORT Transforming Basic Discoveries into Therapeutic Targets Speeding Clinical Testing of New Interventions Mobilizing New Technologies and Tools in PD Therapeutic Development

17 SELECTED LIST OF 2008 MJFF MEETINGS

18 ORGANIZATIONS WITH ACTIVE MJFF AWARDS IN 2008

20 2008 IN PHOTOS

22 2008 DONOR LISTING

THE MICHAEL J. FOX FOUNDATION IS DEDICATED TO FINDING A CURE FOR PARKINSON’S DISEASE 37 FINANCIAL HIGHLIGHTS THROUGH AN AGGRESSIVELY FUNDED RESEARCH AGENDA AND TO ENSURING THE DEVELOPMENT OF IMPROVED THERAPIES FOR THOSE LIVING WITH PARKINSON’S TODAY. ANNUAL REPORT 2008 MJFF ANNUAL REPORT 2 LETTER FROM THE CEO, FOUNDER AND CO-FOUNDER LETTER FROM THE CEO, FOUNDER AND CO-FOUNDER 3 MJFF ANNUAL REPORT

LETTER FROM THE CEO, FOUNDER AND CO-FOUNDER

The Michael J. Fox Foundation has set one clear and simple measure of success: accelerating the key studies, insist that researchers share their Your generosity and support make this delivery of life-changing treatments — and ultimately, a cure — to people with Parkinson’s disease. results early, and tee up academic/ industry possible. Thank you for your commitment partnerships. We keep the most promising ideas on to ending Parkinson’s disease. Together we In 2008 we funded $32.8 million in Parkinson’s phase of drug discovery and development through a strategic course forward. Our eye is on patients’ are speeding transformational therapies research, bringing our total investments since clinical studies. We strive to identify the most needs, clinical studies and better treatments. for PD — and in the process changing the inception to over $140 million. But in our short compelling ideas, then shepherd them through the The researchers we work with around the globe paradigm for how medical research funders history we have come to appreciate that ending vagaries of the therapeutic development process can impact the pace and nature of progress. Parkinson’s disease is not only about spending more and toward the clinic. For most diseases, this quickly come to appreciate how we streamline the money, it is about how we spend it. MJFF targets purposeful view of how to drive research progress research process by challenging them to overcome With gratitude, underfunded, high-risk, translational science, is absent. No one stakeholder exists to align the the “language barrier” common among biologists stepping in where government and industry players efforts of disparate players. No one is in charge of working in different disciplines — even if they can’t or won’t, to drive PD therapies and address finding cures. study the same disease. Scientists will tell you that Katie Hood what’s broken in the broader medical research we are bridgers and connectors, bringing together CEO At MJFF, we’re shooting for nothing less than the enterprise. highly specialized researchers and clinicians who cure for Parkinson’s. Our leadership, drawn from might not otherwise interact, let alone collaborate. Our singular focus on developing new therapies the worlds of both science and business, works In 2008 alone, we brought together more than 460 requires a strategic approach. We review more tirelessly to increase impact by blending the best of them for meetings and workshops to set strategy

Parkinson’s-specific grant proposals than any other of those two worldviews. We proactively manage and future direction. Never before have we had this Michael J. Fox private funder (nearly 800 in 2008), covering every the largest PD portfolio in the world. We prioritize level of discourse and enthusiasm, nor this much Founder optimism that new, transformative treatments are within reach. While we can never be satisfied until we’ve MJFF WORKS TO SPEED PROGRESS ALONG THE THERAPEUTIC DEVELOPMENT PIPELINE The federal government achieved a cure, we’ve named this report for the Deborah W. Brooks annually funds millions in PD research, the vast majority directed at early-stage discovery research. At the opposite end of the pipeline, the tangible progress we’re proud to have driven since Co-Founder pharmaceutical industry spends even more, primarily for late-stage drug development. MJFF works to bridge the “valley of death” between we’ve come on the scene: More researchers working these major pools of capital, prioritizing investments to transform basic discoveries into therapeutic targets and speed clinical testing of new interventions. Our single-minded goal: Shorten the time required for Parkinson’s disease treatments to advance from discovery to FDA approval on Parkinson’s (in 2008 alone we funded nearly (currently 10 to 20 years for a symptomatic treatment and likely even longer for a neuroprotective one). Dollar figures for 2007. $6 million in research undertaken by 25 teams new to PD). More focus on relevance for patients. Industry getting involved earlier. And more FDA Discovery Target Lead Process Pre-clinical Phase I Phase II Phase IIl Validation Optimization Chemistry Development Clinical Trial Clinical Trial Clinical Trial Application scientific hits successfully passing to their next & Approval stage of development, whatever that might be. NIH Biotech and Pharma $29 billion/yr.* $68 billion/yr.* (~$150 million in PD) (~$680 million in PD)

*Source: Research!America, Investment in U.S. Health Research 2007 MJFF ANNUAL REPORT 4 SCIENTIFIC PROGRESS REPORT TRANSFORMING BASIC DISCOVERIES INTO THERAPEUTIC TARGETS 5 MJFF ANNUAL REPORT

TRANSFORMING BASIC DISCOVERIES TARGETING THE SEROTONIN SYSTEM FOR TREATMENT OF LEVODOPA-INDUCED DYSKINESIAS INTO THERAPEUTIC TARGETS Anders Björklund, MD, PhD, of Lund University in “It was apparent to us right away that these findings Sweden and his colleagues are working to target could be important,” says Todd Sherer, PhD, vice iscoveries about the cellular and molecular causes and effects of Parkinson’s disease are published the brain’s serotonin system as a way to lessen president of research programs at MJFF. “The scientific in scientific journals every week, but only a tiny fraction stand a chance of resulting in breakthrough levodopa-induced dyskinesias. Dyskinesias are the evidence for a serotonin role in dyskinesia was uncontrollable, wavy or jerky disruptive movements compelling. And because clinical depression affects Dtherapeutics. Filtering through hits (some already decades old) and systematically evaluating their that are a side effect of long-term dopamine an estimated 15 million people in the United States potential to impact patients’ lives — sooner, rather than later — is a job The Michael J. Fox Foundation replacement therapy. For many patients, they are alone, the serotonin system was already the subject tackles each day. among the most debilitating aspects of living with of intense investigation outside of Parkinson’s. If a PD. The prospect of dyskinesias leads many patients serotonin role in PD were borne out, we could marry Reviewing as many as 800 grant applications a year, our staff PhDs and in-house research team, extensively to delay starting on levodopa, the gold-standard that to what’s already known about the serotonin treatment for PD, or refuse it altogether. system, and potentially accelerate the development trained in neuroscience and project management, continuously monitor and troubleshoot PD research and clinical testing of a new Parkinson’s therapeutic.” developments. Then we aggressively apply financial and intellectual resources to push critical findings Dr. Björklund hypothesizes that serotonin neurons, best $6.9 known for their role in clinical depression and other million forward on the pipeline, assuring their steady advancement toward the clinic and patients. mood disorders, also play a role in Parkinson’s. Over Research funded In our short history, we’ve funded work on approximately 100 therapeutic targets for neuroprotective and three years, with support from the Bachmann-Strauss by MJFF in Dystonia & Parkinson Foundation, MJFF has invested international labs symptomatic approaches to PD, and driven novel treatments to address complications of current therapies. $725,000 in the Björklund team’s development of a in 2008 Some targets have been validated, and work on them continues. But even when outcomes do not meet our serotonin-based treatment for dyskinesias, moving it hopes, taking ideas off the table allows us to redirect limited resources where they are more likely to lead to several steps closer to the clinic than would otherwise be possible. $25.9 practical treatments. million “We think that as Parkinson’s disease progresses The stories on these pages illustrate the MJFF impact: how we prioritize the projects where we believe our and the dopamine system becomes more impaired, Anders Björklund and Manolo Carta Research funded the serotonin system is called on to assist,” says funding and expertise can make the greatest difference, then partner with researchers to speed their work MJFF quickly approved Community Fast Track 2005 by MJFF in U.S. Dr. Björklund. “Serotonin neurons are capable of labs in 2008 toward relevance for patients. funding to validate the results in a larger study. When converting levodopa to dopamine, and can store and that study confirmed the pilot findings, MJFF sent more release newly synthesized dopamine, as dopamine money to drive additional experiments. Within another neurons do in a healthy brain.” year the scientists had identified two specific serotonin In intriguing pilot experiments in pre-clinical models, receptors, 5-HT1A and 5-HT1B, whose activation When Proteins Misfold: Dr. Björklund observed that manipulating the activity produced a near-complete suppression of levodopa- Driving Validation of a Novel Neuroprotective Target of certain serotonin neurons had a profound ability to induced dyskinesia in pre-clinical Parkinson’s models. reduce the severity of levodopa-induced dyskinesias. At the same time, they screened the scientific literature In 2005, scientists working in tiny worms known as C.elegans demonstrated that the protein TorsinA, which occurs naturally in The researchers brought the data to MJFF for to identify known candidate drugs that activate both the brain, can protect dopamine neurons from death. While TorsinA’s normal function is not entirely understood, it is thought to evaluation. receptors and may be suitable for clinical use. In be a “chaperone” — a molecule that helps cells repair damaged or misfolded proteins. Increasing TorsinA activity, researchers December 2008, Manolo Carta, PhD, a member of the hypothesize, may improve cells’ ability to repair themselves. Björklund lab, received funding for another round of Now MJFF is funding an academic-industry collaboration to validate the C.elegans results in a second pre-clinical model of experiments, which could be the final pre-clinical work Parkinson’s disease. The goal: establish enough evidence to compel an industry partner to launch a program that would fully required before a Phase 1 clinical trial. flesh out the therapeutic potential of compounds targeting TorsinA function. “We’ll pay particular attention to the long-term effects Schematic representation of the “The modulation of TorsinA points to a new direction for treating PD at what may be one of its root causes — the toxic effects of hypothesized role of altered serotonin of these drug candidate compounds,” says Dr. Carta. misfolded proteins that accumulate in critical brain cells,” says lead investigator David Standaert, MD, PhD, of the University of (5-HT) activity leading to dyskinesia “The results will be highly relevant for the design of Alabama at Birmingham. “If the protective effect of TorsinA seen in C.elegans is also found in mammalian pre-clinical models of a proof-of-concept clinical study investigating the the disease, our work could spark meaningful investment in this promising new target.” efficacy of this approach to treat dyskinesia in people with PD.” Dyskinesias MJFF ANNUAL REPORT 6 SCIENTIFIC PROGRESS REPORT TRANSFORMING BASIC DISCOVERIES INTO THERAPEUTIC TARGETS 7 MJFF ANNUAL REPORT

“I’m enthusiastic about partnering with The Michael J. Fox Targeting Glutamate Receptors for Sustained Foundation because they share my team’s commitment to push Symptomatic Relief promising therapeutics toward the clinic and patients. MJFF MJFF is partnering with P. Jeffrey Conn, PhD, to jump-start a new class of symptomatic understands and provides the kind of support — financial and PD treatment targeting the glutamate system. (To learn more about glutamate’s potential intellectual — required to speed the translation of research therapeutic role in PD, see “Anatomy of a Novel Target” below.) discoveries into new treatments.” Dr. Conn, Vanderbilt University’s Lee E. Limbird Professor of Pharmacology and Director of the —Jeff Conn Program in Drug Discovery, came to MJFF with evidence that increasing the activity of certain glutamate receptors could alleviate symptoms in pre-clinical models of PD. He received Target Validation 2005 funding to home in on the right receptors for further study, and to identify molecules capable of boosting the activity of those receptors. That work substantiated the mGluR4 receptor as an especially promising target for a new symptomatic therapy.

Typically, once promising drug leads are identified, they must be engineered into a compound Targeting Inflammation in PD suitable for clinical testing. This phase of work requires an interdisciplinary team with expertise spanning medicinal chemistry, molecular biology and in vivo studies. Late in 2007, with support For decades researchers have worked to understand the role of chronic inflammation from The Edmond J. Safra Foundation, MJFF granted Dr. Conn a $4.4 million LEAPS (Linked Efforts to Accelerate Parkinson’s Solutions) award to assemble and lead such a team for further work in the death of dopamine neurons in PD. MJFF is exploring multiple approaches to on the mGluR4 receptor. The LEAPS team spent 2008 more thoroughly characterizing mGluR4’s characterize the relationship between inflammation and Parkinson’s, and to validate therapeutic potential while simultaneously generating a viable drug candidate to target it. Further therapeutic targets that could slow or reverse inflammation-related pathology. optimization is ongoing in the first half of 2009, with pre-clinical testing of the most promising candidate on deck for the latter part of the year. In 2003 Kalipada Pahan, PhD (then a faculty member at the University of Nebraska Jeff Conn Malú Tansey Medical Center), received funding to study the role of naturally occurring protein NF-kB in the production of various inflammatory molecules. Working in pre-clinical PD models, Dr. Pahan’s team demonstrated that chains of amino acids known as NBD peptides, which control inflammation and protect neurons, can rescue dopamine Anatomy of a Novel Target: Exploring Glutamate neurons from death. In 2008 MJFF brought Dr. Pahan (now at the Rush University Medical Center) one step closer to the clinic by funding him to test the efficacy of NBD While the dopamine system has long been the primary dopamine replacement at all,” says MJFF awardee peptides in more predictive models of PD. If the results show promise at this stage, interest of PD researchers, recent evidence supports Stephen Traynelis, PhD, of Emory University. “My NBD peptides could enter the clinic and become the basis of a novel drug to modify the Stephen Traynelis the potential of glutamate, another neurotransmitter, lab is exploring whether decreasing the activity of a progression of PD. as a therapeutic target for PD. particular glutamate receptor may lower the known overactivation of three different sets of neurons in Like dopamine, glutamate is a signaling molecule Malú Tansey, PhD, of the UT Southwestern Medical Center at Dallas is pioneering a Parkinson’s.” that plays a role in transporting brain messages and separate inflammation-based therapeutic approach to PD. Dr. Tansey was first funded controlling body functions. Early findings suggest MJFF has funded 11 researchers in six separate labs, in 2003 to investigate a pro-inflammatory protein called Tumor Necrosis Factor that manipulating specific parts of the glutamate including Dr. Traynelis’s, to advance novel treatment (TNF). Based on exciting progress from that project, MJFF staff elected to provide system could alleviate Parkinson’s symptoms and paradigms based on glutamate. supplemental funding to Dr. Tansey in 2004 and 2005. She went on to demonstrate complications while bypassing the dopamine system in pre-clinical models of PD that dopamine neurons can be rescued from death by altogether. Alternatively, it may be possible to develop “A great deal of Parkinson’s disease research, inhibiting the activity of TNF. In 2008 the Foundation funded Dr. Tansey’s current Electron micrograph a dual or complementary treatment approach, in including the validation of glutamate as a therapeutic investigation of a gene therapy approach selectively targeted at soluble TNF that could image of glutamate receptor which glutamate-based therapies lessen patients’ target, is at a stage where scientists have not immunoreactivity yet identified the precise tactic that will yield the inhibit inflammation, potentially slowing or stopping the progressive loss of dopamine needs for dopamine-based therapies — in turn greatest therapeutic benefit,” says Katie Hood, CEO. Midbrain cells neurons in Parkinson’s disease. reducing the debilitating side effects of long-term expressing dopamine replacement. “Throughout our portfolio, MJFF identifies multiple potentially promising approaches and funds them simultaneously. therapeutic “Dopamine replacement therapies lose effectiveness Even if one strategy fails, another may still be making dominant/ over time and bring serious side effects. And many strides toward practical relevance for patients.” negative TNF disruptive symptoms of Parkinson’s don’t respond to (green) MJFF ANNUAL REPORT 8 SCIENTIFIC PROGRESS REPORT SPEEDING CLINICAL TESTING OF NEW INTERVENTIONS 9 MJFF ANNUAL REPORT

SPEEDING CLINICAL TESTING COULD A HIGH-BLOOD-PRESSURE DRUG SLOW THE PROGRESSION OF PD? OF NEW INTERVENTIONS

In December 2008 MJFF announced a three-year Following enthusiastic peer review, and with support award of $2 million to fund a Phase 2 clinical trial from the Mann Family Foundation in memory of its linical research for any disease is expensive and requires unique and distinct expertise. No matter investigating isradipine, an FDA-approved high blood founder, Fred Mann, MJFF awarded the investigators a $2-million Clinical Investigation Award. The award how promising a new treatment strategy, shepherding it through trials and regulatory approval is pressure drug. Isradipine is in a class of high-blood pressure medications that work by blocking the activity allowed the researchers to begin the trial in 2009 Ca lengthy and costly process. An entire team must be assembled with the skill and experience to of calcium channels, which help cells fire electrically. in 100 patients with early idiopathic PD. If the trial conduct research in humans. Individuals who fit the study’s needs must be found and agree to enroll. Once D. James Surmeier, PhD, a noted Parkinson’s researcher yields a critical mass of data on isradipine’s efficacy in the intervention begins, tests must be performed at regular intervals, often requiring multiple visits to a at Northwestern University in Chicago, developed a Parkinson’s disease, other funders will have a strong theory that hyperactive calcium channels may stress incentive to expand the Phase 2 trial and continue into clinical center. Results must be scrupulously assessed and reported to the appropriate regulatory bureau dopamine neurons, leading them to shut down or die. Phase 3 — helping speed this potential breakthrough with compelling evidence that the new treatment represents a marked improvement over existing ones. He hypothesized that drugs like isradipine might reduce to PD patients. this stress, thereby slowing or stopping the progression In addition to these standard hurdles, Parkinson’s disease trial sponsors lack objective tools and scales for of Parkinson’s disease. In 2007 he published this measuring the effects of disease-modifying interventions. This represents a serious challenge in PD clinical hypothesis in the prestigious scientific journal Nature.

research: Biotech and pharmaceutical companies, whose resources are needed to carry new therapeutics No current Parkinson’s treatment has been definitively +isradipine control +rotenone control control +MPTP control +MPTP (acute) proven to modify the progression of PD. Available * * * * * * * * over the finish line, are unlikely to risk investing in trials where the likelihood of clear and marketable 8 4 10 20 therapies mask symptoms while the underlying ) 2 outcomes is low. 8 pathology continues to worsen. A neuroprotective 6

/mm 3 15 treatment is the ultimate goal of Parkinson’s research. 3 MJFF shares patients’ urgency to overcome these challenges and bring new therapies to market as fast as 6 Dr. Surmeier’s article suggested a potential new 4 2 10

possible. In prioritizing clinical trials, we emphasize proof-of-principle and first-in-human studies that can esses (X10 4 c

research path to such a treatment. MJFF research staff Mis-steps (%) Firing rate (Hz) ro

p 2 t 1 5 TH Cells/SNc (X1000) alter the risk profile of a given treatment. We also step in as needed to help assemble and organize the right encouraged him to apply for immediate Foundation c 2 ta n funding. Within weeks of his first conversation with I teams, lend expertise to biotech and pharmaceutical companies testing the PD waters, vet the Parkinson’s 0 0 0 0 MJFF, Dr. Surmeier had a $75,000 Rapid Response potential of drugs approved for other diseases, and sponsor trials where intellectual property or patent naive naive naive naive Innovation Award in hand to expand pre-clinical testing isradipine isradipine isradipine isradipine issues reduce companies’ incentive to get involved. of his hypothesis. pre-exposure pre-exposure pre-exposure pre-exposure

Dr. Surmeier’s experiments quickly demonstrated Potential disease-modifying effects of isradipine in a pre-clinical model of PD considerable promise for isradipine in slowing Parkinson’s progression. In October 2008 the results Why Test Other Diseases’ Drugs Over the 10 to 15 years it takes to turn a target into a marketable drug, a pharmaceutical company were met with excitement at the Foundation’s second typically spends $800 million or more. One reason it takes so long and costs so much is that the PD Therapeutics Conference in Chicago. for Parkinson’s? An important cautionary note: While MJFF is funding clinical trials on supplements and safety of every new candidate drug for human use must be carefully established. The next steps were clear: determine requirements to drugs already available for purchase or prescription, people with Parkinson’s (other than those who ultimately enroll in these trials) should not begin taking these agents as That’s why MJFF pays close attention when a drug already approved by a regulatory body shows take these findings to a clinical trial and see whether part of a Parkinson’s disease treatment regimen without the explicit recommendation of potential to benefit Parkinson’s. If MJFF funding can help demonstrate efficacy against PD, the drug the promising pre-clinical data carried through to their doctor. Evidence to date has not yet definitively proved a benefit in PD, and these can advance much more rapidly to clinical testing in Parkinson’s patients. people with PD. Safety would be a particular concern: substances carry potential health risks, which doctors will carefully monitor in trial Many people with Parkinson’s already have low blood participants. It is crucial that all care and treatment decisions related to Parkinson’s In addition to the projects described on these pages, the Foundation is funding Erwan Bezard, PhD, pressure, so lowering blood pressure further could disease and any other medical condition be made in consultation with a physician or of the University of Bordeaux, France, to investigate statin (high cholesterol) drugs to alleviate prove dangerous. Working closely with Dr. Surmeier other qualified medical professional. levodopa-induced dyskinesias. And Marina Emborg, MD, PhD, of the University of Wisconsin, and his Northwestern colleague Tanya Simuni, MD, Madison, is exploring the diabetes drug pioglitazone as a neuroprotective treatment for Parkinson’s the Foundation mapped the route to a pilot Phase 2 disease. Her work, funded by MJFF since 2005, has demonstrated that pioglitazone causes clinical trial to establish optimal dosage and possible functional benefits in pre-clinical models of PD. “Pioglitazone already has FDA approval and a side effects. well-established safety profile,” says Dr. Emborg. “With further promising pre-clinical outcomes, it could be ready for clinical studies in Parkinson’s patients as soon as 2010.” Iwona Strycharska-Orzyk MJFF ANNUAL REPORT 10 SCIENTIFIC PROGRESS REPORT SPEEDING CLINICAL TESTING OF NEW INTERVENTIONS 11 MJFF ANNUAL REPORT

“Only MJFF would have the incentive and flexibility to fund a CERE-120 AND THE FUTURE OF TROPHIC-BASED APPROACHES TO PD trial like ours in a matter of months.” — Michael Schwarzschild

In November 2008 the Parkinson’s community was that CERE-120 had exerted a therapeutic effect. The disappointed to learn that Ceregene Inc.’s CERE-120, problem was exacerbated, as always in PD clinical a gene therapy approach to treat Parkinson’s patients trials, by the lack of a biomarker that could objectively INVESTIGATING INOSINE with trophic factor neurturin, had not demonstrated measure treatment effects. greater benefit than a placebo in a double-blind, Nonetheless, The Michael J. Fox Foundation continues controlled Phase 2 clinical trial. Trophic factors (also In April 2008 the journal Archives of Neurology that finding funding for this trial might take years,” to see real promise in trophic-based approaches to known as neurotrophic factors or growth factors) are published an epidemiological study showing that Dr. Schwarzschild said. “Only MJFF would have the treating PD — even, potentially, in CERE-120 itself. specialized proteins that protect and nurture neurons, people with early PD who had elevated blood levels of incentive and flexibility to fund a trial like ours in a Lessons learned from this trial will be of great value in including the dopamine neurons that die in Parkinson’s urate — a natural antioxidant in the blood — were matter of months.” He and his colleagues decided to refining future attempts to treat PD with trophic factors, disease. Ceregene’s Phase 2 trial of neurturin was able to forgo dopamine replacement therapy longer approach the Foundation. noted Todd Sherer, PhD, vice president of research partially supported by The Michael J. Fox Foundation than people with lower urate levels. Those with higher programs at MJFF. “Going forward, the data from the Michael Schwarzschild “Dr. Schwarzschild and his team brought their results with leadership funding from the family of Board urate levels also showed less severe changes on brain Phase 2 CERE-120 trial will help researchers make to us knowing that we were the only organization likely member Daniel E. Spitzer, MD. A successful Phase 1 scans. critical adjustments in how and where they attempt to trial also was funded by MJFF with principal support to jump on inosine as a strategy for PD because of its deliver trophic factors to the Parkinson’s brain. This from The Pioneer Fund, a private family foundation “Our findings, combined with prior knowledge of urate’s promise as a new treatment, regardless of IP value or could be the key to future trials’ success.” that supports endeavors including medical research. protective properties in laboratory studies, raised the profit margin considerations,” says Katie Hood. “This “There’s no question that outcomes of trophic-based possibility that urate-elevating strategies could be is just the kind of gap between the bench and the Phase 2 trial participants, all Parkinson’s patients, trials have been frustrating so far,” added Katie Hood. used to slow the neurodegeneration of Parkinson’s clinic that our Foundation exists to bridge.” were split into two groups — one group received active “Our Foundation shares that frustration with patients. disease,” says the study’s lead author, Michael CERE-120 and one received inactive placebo. In both With support from The Edmond J. Safra Foundation, But far from giving up, we’re working aggressively Schwarzschild, MD, PhD, of Harvard Medical School. groups, 70 percent of participants showed a five- MJFF awarded the team a LEAPS award of up to $5.6 to learn from past outcomes in order to solve the point or greater improvement in their UPDRS motor Epidemiological findings are intriguing, but must be million to undertake the Phase 2 study. The goals are problems that have hindered these treatments to off scores. This made it a challenge to demonstrate tested clinically. Dr. Schwarzschild and his colleagues to assess the safety of using inosine to raise blood date. MJFF believes it is possible to obtain the same wanted to take the next logical step: determining urate levels, and to determine optimal dosage. The beneficial response in PD patients that has been whether raising urate levels in PD patients might researchers plan to begin patient enrollment in observed time and again in pre-clinical studies.” slow the progression of Parkinson’s. They immediately mid-2009 and are applying for NIH funding for a began designing a Phase 2 clinical trial to investigate larger trial. the potential of a naturally occurring chemical, Despite the promising findings so far, Dr. Exercise and PD: Getting to the Bottom of the Connection inosine, which is converted by our bodies into urate. Schwarzschild cautioned, people with Parkinson’s As inosine is widely available to consumers at (other than those who enroll in this trial) should not There is some scientific evidence that exercise holds specific benefits for people with health food and vitamin stores, no corporate entity start taking inosine. Parkinson’s disease. had the incentive to sponsor clinical research to “The potential benefits of urate must be tempered “Personally, I believe it’s quite likely that exercise may prove to be more beneficial than some definitively assess its potential in Parkinson’s. “When against the risks of elevated urate levels, which of the pharmaceutical agents available to PD patients,” says Lisa Shulman, MD, of the we thought about potential funders, it was clear University of Maryland. “With MJFF funding, my team is working to definitively show that include gout and kidney stones. From what we know exercise can be a beneficial addition to overall management of the disease. And exercise now, urate elevation should be attempted only in the is something that can restore a sense of control and reduce feelings of helplessness. Having context of a closely monitored clinical trial, in which a chronic disorder doesn’t mean you need to be a ‘passive patient’; you don’t have to throw in potential benefits and risks are carefully balanced.” Lisa Shulman the towel.”

MJFF has invested over $2.7 million in exercise studies to date. Our priorities: establishing concrete evidence of how exercise may alleviate PD symptoms, or even slow or stop disease progression; and accelerating identification of the most effective forms of exercise for people with PD. MJFF ANNUAL REPORT 12 SCIENTIFIC PROGRESS REPORT MOBILIZING NEW TECHNOLOGIES AND TOOLS IN PD THERAPEUTIC DEVELOPMENT 13 MJFF ANNUAL REPORT

MOBILIZING NEW TECHNOLOGIES AND TOOLS IN PD THERAPEUTIC DEVELOPMENT

hile new genetic and cellular targets have invigorated pre-clinical and clinical Parkinson’s ALPHA-SYNUCLEIN: SILENCE MAY BE GOLDEN Structure of the alpha-synuclein research over the last 10 years, converting these discoveries into practical treatments requires protein as it may deliberate and strategic investment in the development of new research technologies and tools. The naturally occurring brain protein alpha-synuclein In 2005 work funded under Target Validation, look inside a neuron. W is a major constituent of Lewy bodies, protein clumps researchers at Alnylam Pharmaceuticals and Mayo The portion colored In 2008 MJFF worked to apply novel concepts to PD at every stage of development. RNAi technology could that are the pathological hallmark of PD. Recent studies Clinic Jacksonville (Florida) demonstrated that siRNAs reddish orange in this (including some funded by MJFF as early as 2002) reduced alpha-synuclein levels in pre-clinical models of representation seems to be the critical part bring relief by silencing molecules whose overexpression is implicated in PD. New methods ranging from have shown that alpha-synuclein may play a role in Parkinson’s disease. Now a $3.8-million award under for forming clumps, a nasal spray to gene therapy might allow for practical and non-invasive delivery of therapies that do not the development of rare familial cases of PD, as well the Foundation’s LEAPS (Linked Efforts to Accelerate as found in Lewy naturally cross the blood-brain barrier. as the more common sporadic form of the disease. Parkinson’s Solutions) initiative, granted with support bodies, whereas the Though its precise role in PD remains veiled, growing from The Edmond J. Safra Foundation, is funding an “tail” section (purple) Acceleration also requires that we facilitate and lead the development of research tools that could shift evidence supports the hypothesis that decreasing alpha- interdisciplinary consortium of scientists to push this normally helps prevent clumping. paradigms across the board for pre-clinical and clinical research. Since 2002 MJFF has led the hunt for synuclein in the brain could be one way to slow or stop work toward clinical relevance. Parkinson’s progression. biomarkers to diagnose and measure the progression of Parkinson’s disease, vital tools for the development The LEAPS team, led by Mayo Clinic’s Matt Farrer, PhD, of disease-modifying therapies. And in our quest to create pre-clinical tools that can help researchers better While aggressive work is ongoing toward a traditional with collaborators at Alnylam and The Parkinson’s small-molecule pharmacological approach to regulating Institute and Clinical Center, is working to identify an understand PD as well as screen new therapies, our portfolio includes the development of new genetic alpha-synuclein, to date no drugs that can lower the optimal alpha-synuclein siRNA drug candidate, then models and an exploration of induced pluripotent stem cell technology to develop personalized models of protein’s levels in the brain have advanced to clinical establish efficacy and the “therapeutic window” for Parkinson’s disease. We are also exploring how the Internet may change the way research gets done — trials. MJFF believes that other approaches are worth brain infusion in pre-clinical models. If successful, this exploring. Since 2005, MJFF has been funding project could ultimately lead to the development of an as it has changed so much else in the past decade. investigation of RNA interference (RNAi), also known alpha-synuclein siRNA candidate drug that, in the future, as gene silencing, as a strategy for reducing alpha- could be tested in PD patients in Phase 1 clinical trials. synuclein in the Parkinson’s brain.

Nanotechnology for Parkinson’s Disease RNAi is a mechanism naturally present in all body cells. “Small interfering RNA” (siRNA) molecules In December 2004 Copernicus Therapeutics, Inc., of Cleveland, Ohio, first published results of a are able to silence a gene’s expression of a particular human clinical trial for cystic fibrosis showing that nanotechnology — condensing molecules of protein through the destruction of messenger RNA, DNA into particles tiny enough to penetrate the membrane surrounding a cell’s nucleus — can be the molecule that contains the instructions for protein used as a nonviral approach to gene therapy. Now, MJFF is working to determine the feasibility of synthesis. Since the discovery of RNAi in the 1990s, a nanotechnology gene therapy approach for Parkinson’s disease. researchers have worked to harness this natural Under the Foundation’s 2007 Rapid Response Innovation Awards, which provide fast funding for capability of small RNA molecules to silence genes’ high-risk, high-reward concepts that could kick-start new treatment approaches to Parkinson’s, expression of proteins linked to disease — such as David Yurek, PhD, successfully introduced condensed DNA coding for trophic factor GDNF; these alpha-synuclein in PD. nanoparticles are small enough to enter brain cells. These particles were safely injected into Molecules of “The Michael J. Fox Foundation is optimistic about condensed DNA that the brains of pre-clinical models of PD and successfully caused the cells of interest to begin aggressively pursuing RNAi therapeutics for PD,” says could be used in gene manufacturing GDNF. Schematic representation of the therapeutic mechanism of therapy to treat PD CEO Katie Hood. “It’s a completely novel approach, but RNAi. Left to right: A short interfering RNA (siRNA) is designed In 2008 MJFF approved supplemental funding for Dr. Yurek, a faculty member at the University of one that could lead to a major scientific leap forward in to correspond to a gene target of interest. The siRNA is then synthesized with drug-like properties. The modified siRNA Kentucky, to partner with Copernicus Therapeutics, the provider of condensed DNA, to compare terms of improving patients’ quality of life.” penetrates the cell membrane and harnesses the RNAi mechanism several different formulations of DNA coding GDNF. The goal is to optimize a particular formulation for gene silencing to achieve a therapeutic effect. for long-term expression in pre-clinical models and determine whether the treatment results in improved motor function. If the project is successful, it could help give rise to an entirely new strategy for treating PD. MJFF ANNUAL REPORT 14 SCIENTIFIC PROGRESS REPORT MOBILIZING NEW TECHNOLOGIES AND TOOL IN PD THERAPEUTIC DEVELOPMENT 15 MJFF ANNUAL REPORT

Outsmarting the The blood-brain barrier (BBB) is critical to human health. It surrounds the brain and keeps out Using Reprogrammed Cells to Develop a New Model agents that could do us harm. Unfortunately, this thin membrane of tightly packed cells is an of LRRK2-associated PD Blood-Brain Barrier overachiever. In addition to putting up a velvet rope for viruses and other pathogens, it prevents many potentially beneficial therapies for neurodegenerative diseases, including Parkinson’s, from entering as well. U.K. researchers Patrick A. Lewis, PhD, of the Institute of Neurology and John Hardy, PhD, of University College London have received MJFF funding to use induced pluripotent stem cells (iPS So-called large- and small-molecule treatments work by causing therapeutic molecules to enter cells) to develop an entirely new cellular model of Parkinson’s disease. IPS cells are created when the bloodstream. From the blood, these molecules are taken up by the appropriate body cells to scientists “reprogram” skin cells into an embryonic-like state. Dr. Lewis will engineer iPS cells bring about the desired beneficial effect. Small-molecule treatments make up the majority of orally from the skin cells of people with a form of Parkinson’s linked to a mutation in the LRRK2 gene. administered treatments on today’s market. Large-molecule treatments typically involve the use of The cells will then be converted into the specific dopamine-producing cells within the substantia specialized proteins. To rescue dopamine neurons from death, small or large therapeutic molecules nigra that die in PD. By comparing these engineered cells to those from individuals who do not must find their way into the brain. But the BBB prevents them from doing so. have a genetic disposition to Parkinson’s disease, the investigators hope to discover what makes the LRRK2 cells different and more susceptible to a premature demise. This, in turn, could The Foundation is committed to driving new and novel approaches to drug delivery throughout its help uncover new molecular and cellular pathways involved in PD as well as new targets for drug portfolio of PD research investments. And in 2008 MJFF and The Kinetics Foundation co-launched a treatment. $2-million initiative, Improving Delivery of Parkinson’s Disease Therapeutics to the Brain, dedicated to improving therapeutics delivery across the BBB as well as refining surgical approaches that Induced pluripotent “If this project succeeds, we will have developed a new PD model from which we can learn more stem cells (iPS cells) today represent the only option for getting many therapeutics of interest into the brain. about the mechanisms underlying the disease — knowledge essential to developing better generated from a patient carrying a treatments,” says Dr. Lewis. “In addition to providing a valuable resource for basic discovery mutation in LRRK2 research into Parkinson’s, such a model would also provide an important testing ground for therapies to reverse any deficits that we uncover.” Ancient History Meets Science Fiction: A “Trojan Horse” Nasal Spray: An That Can Sneak GDNF across the Blood-Brain Barrier On-the-Nose Approach Structure of a fragment of a LRRK2- related protein from a bacterial equivalent to Delivering GDNF? of the PD-related kinase LRRK2. One In 2006 William M. Pardridge, MD, of the University the GDNF gene to the desired areas of the brain, of the proteins in the bacteria has an of California, Los Angeles, was funded by MJFF to resulting in lasting improvement in motor function Barbara Waszczak, PhD, a professor at evolutionarily conserved version in humans. vet the potential of “Trojan Horse” technology to and brain biochemistry. Northeastern University, is focusing on This structure is therefore a basis for overcome the challenge of getting trophic factors the potential of a nasal spray to treat understanding how mutations in human LRRK2 cause PD — and how we might Building on these promising early results, in 2008 much more than the common cold. In across the blood-brain barrier (BBB). Trojan Horse modify this. technology aims to fuse a large molecule, which MJFF awarded $1 million to Santa Monica-based 2007 Dr. Waszczak approached MJFF normally cannot cross the BBB, to an antibody that biotech ArmaGen Technologies, Inc., for a project with her idea to use an intranasal naturally can. The antibody hides the large molecule using Trojan horse technology to re-engineer the method to deliver GDNF to the brain from the BBB sentry — as the Trojan horse of GDNF protein to cross the blood-brain barrier. The and quickly received a Rapid Response Homer’s Iliad hid Greek soldiers, allowing them to end goal is to create a safe and effective treatment Innovation Award to investigate the enter Troy — and ferries the attached protein from in which the GDNF protein, fused to a genetically efficacy of delivering the protein through the blood to the target site in brain. engineered antibody naturally capable of crossing the nose. She found that when given the blood-brain barrier, can simply be injected into intranasally, GDNF reached the brains “Prior attempts to treat PD may have failed because the blood. of pre-clinical models in sufficient of problems with drug delivery,” says Dr. Pardridge. “Trojan horse technology has intrigued PD researchers quantities to protect dopamine neurons “Trojan Horse technology provides a new approach to from an experimental neurotoxin. target therapeutic agents of interest to the proper for years,” says Gene Johnson, PhD, chief scientific areas of the Parkinson’s brain.” advisor to MJFF. “The Foundation’s goal is to speed Now, with funding under the the timetable for determining just how real the Foundation’s 2008 Improving Delivery of Dr. Pardridge demonstrated in pre-clinical models potential here is.” Parkinson’s Disease Therapeutics to the that a single intravenous injection transported Brain, Dr. Waszczak’s team is using GDNF provided by Amgen to determine if this “Intranasal delivery is widely used to treat many diseases. If proven safe delivery method results in nasal toxicity and how much GDNF actually reaches in PD, it could be a practical intervention to benefit millions of people the target area of the brain. with Parkinson’s worldwide.” — Barbara Waszczak MJFF ANNUAL REPORT 16 SCIENTIFIC PROGRESS REPORT 17 MJFF ANNUAL REPORT

“Our partnership with MJFF has allowed us to upgrade the SELECTED LIST OF 2008 MJFF MEETINGS infrastructure of our Brain and Body Donation Program and collect data that will identify new predictors of cognitive dysfunction, early parkinsonian pathology in non-symptomatic subjects, and PD-like pathology in body tissue not previously The Power to Convene implicated in PD.”— Charles H. Adler, MD, PhD, Professor of Neurology, Mayo Clinic College of Medicine, and Co-Principal Investigator of MJFF’s Prescott Family Initiative at The Driving research toward transformative treatments requires not only better communication, but also Arizona Parkinson’s Disease Consortium cooperation and multidisciplinary thinking. In 2008 MJFF brought together more than 460 top researchers from academic and industry labs all over the world for formal and informal face-to-face conferences, summit meetings and workshops. These activities are not ends in themselves, but rather catalysts for concrete action steps — new grant programs, funding for critical tools and resources, novel collaborations Could the Internet Change the Way Research Gets Done? and other tactical interventions to move promising ideas forward faster. Following are highlights of approximately 60 scientific sessions, grant reviews and assessments that we What if it were possible for any interested studies under way for the use of Web technologies individual to switch on their personal computer to gather epidemiological data. Additionally, in sponsored or co-sponsored in 2008 to help set strategy and future direction for the entire field. In addition to 62: and participate in clinical research — without September four research teams were awarded these meetings, our full Scientific Advisory Board convened in Fort Lauderdale in March, and our Executive Number of 2008 ever needing to leave their home? The Michael J. $1 million under the Foundation’s Developing meetings between Scientific Advisory Board met in June and November. Fox Foundation thinks such a development would and Validating Web-based Clinical Assessments MJFF and industry to discuss funding and lead to increased participation in clinical research for Parkinson’s Disease initiative. Teams will test Drug Delivery Workshop, January 16 Fetal Tissue Transplants and PD Pathology Summit, strategic partnership at lower cost; amplification of patients’ voices in different methods of remotely gathering data on (Co-convened with The Kinetics Foundation) September 4 possibilities the research process; more data for researchers aspects of Parkinson’s ranging from cognitive and Experts in drug delivery worked to improve understanding of Experts discussed new findings on long-term survival and to work with; and, ultimately, faster progress motor function to visual and spatial symptoms, challenges in delivering therapeutics to the brain. status of fetal transplant tissue in Parkinson’s patients and toward a cure. as well as develop Spanish-language Web-based implications for cell replacement strategies in PD. assessments. Demonstrating Disease-modifying Effects for the 769: With acceleration of new treatments MJFF’s Treatment of Parkinson’s Disease: Drug Development and Second Annual PD Therapeutics Conference, September 15 Number of grant “The Internet has changed so much of what we do Regulatory Issues, April 28-29 More than 120 academic and industry researchers and business applications chief goal, the appeal of technology-enabled (Co-convened with the United States Food and Drug development professionals attended the only major scientific reviewed by MJFF approaches to PD research is clear. In 2008 the in our lives over the last 10 years — how we buy, in 2008 Foundation funded five projects to develop Web- how we communicate, how we find information, Administration, the American Association of Pharmacological symposium exclusively focused on speeding PD therapeutics Scientists and the Parkinson Study Group) development. based tools — such as online questionnaires, how we do business,” says CEO Katie Hood. “It’s Experts in Parkinson’s disease, drug development, quantitative or motion-sensor devices — that could enable hard to believe it can’t have a similar impact on clinical pharmacology and statistics worked toward a consensus LRRK2 Biology, November 5 scientifically valid PD research to be conducted how we do research.” on objective endpoints for clinical trials of neuroprotective Leading experts set priorities for investigation into the biology outside the confines of the clinic. therapies. and pathology of the Parkinson’s disease-associated gene LRRK2. In May MJFF announced that it would support a MJFF Research Strategy Assessment, August 6 partnership between personal genetics company External experts objectively assessed MJFF activities to date and LRRK2 Cohort Meetings, December 4 and 12 23andMe and The Parkinson’s Institute and provided recommendations for future programmatic activities. PD scientists discussed the unique data or information that Clinical Center to develop Web-based tools and could be provided by cohorts of Ashkenazi Jewish and North African Arab-Berber individuals with PD-implicated LRRK2 surveys to gather information from people with mutations. Parkinson’s in a scientifically meaningful way. That project is still in progress, with validation “The topics and attendees, format and fast pace make the PD Therapeutics Conference a wonderful venue for understanding clinical implications of the most current PD research.” — Lisa McConlogue, PhD, Elan Pharmaceuticals, Inc. MJFF ANNUAL REPORT 18 SCIENTIFIC PROGRESS REPORT 19 MJFF ANNUAL REPORT

ORGANIZATIONS WITH ACTIVE MJFF AWARDS IN 2008

The most promising projects, undertaken by the best teams, at the right times. Spaulding Rehabilitation Hospital Australia Israel State University of New York at Buffalo University of Melbourne CellCure Neurosciences Ltd. Each year The Michael J. Fox Foundation receives hundreds of grant proposals from scientists Sun Health Research Institute Hebrew University of Jerusalem Canada SUNY Downstate Medical Center NeuroDerm Ltd. based at medical research institutes, universities and biotech and pharmaceutical companies all Allon Therapeutics Temple University ProNeuron Biotechnologies over the world. In reviewing these applications, our research staff and expert advisors are always Molecular Biometrics The Salk Institute for Tel Aviv Sourasky Medical Center Toronto Western Hospital seeking the same thing — ideas ready to be translated into new treatments, teams with the Biological Studies University of Ottawa Italy TheraLogics, Inc. expertise to execute those ideas, thoughtful and realistic work plans, and outcomes that will take San Raffaelle Institute Chile us closer to breakthrough treatments and a cure for PD. MJFF had active research projects with the Thomas Jefferson University Tufts University University of Chile Netherlands following institutions and companies in 2008. UMDNJ-Robert Wood Johnson Medical Academic Medical Center 25 China School Leiden University Medical Center Number of labs Capital University of Medical Sciences funded by MJFF United States Massachusetts General Hospital University of Alabama Maastricht University Hospital in 2008 that had 23&Me, Inc. (Harvard Medical School) University of Alabama at Birmingham Denmark Nijmegen University Medical Center never worked in Acadia Pharmaceuticals Massachusetts Institute of Technology University of California, Berkeley Lundbeck A/S University of Aarhus PD before University of California, Los Angeles Amicus Therapeutics Mayo Clinic Finland New Zealand University of California, San Diego ArmaGen Technologies, Inc. McLean Hospital (Harvard Medical School) University of Helsinki University of Auckland (New) Beth Israel Deaconess Medical Center Memorial Hospital of Rhode Island University of California, San Francisco University of Aarhus $5.9 (Harvard Medical School) MIGENIX Corporation University of Cincinnati Norway Beth Israel Medical Center Mount Sinai School of Medicine University of Florida France DiaGenic U.S./Int’l million École Normale Superieur Biodesy, LLC National Institute of Neurodegenerative University of Kentucky Portugal Amount of 2008 INSERM Boston University Disease and Stroke, NIH University of Maryland Institute for Molecular Medicine research Brandeis University Nebraska Health and Human University of Miami Salpêtrière Hospital funded by MJFF C2N Diagnostics Services System University of Michigan Joseph Fourier University Spain in those labs California Institute of Technology Neurocrine Biosciences University of Nebraska University of Bordeaux Hospital General Yague Trophos Caliper Life Sciences (Xenogen) NeuroHealing Pharmaceuticals, Inc. University of Pennsylvania Sweden Case Western Reserve University Northeastern University University of Pittsburgh Germany Karolinska Institute Ceregene, Inc. Northern California Institute for Research University of Rochester Johann Wolfgang Goethe University Lund University Sweden Clemson University and Education University of South Florida Paracelsus Elena Klinik Switzerland Cleveland Clinic Northwestern University University of Tennessee Philipps University Marburg Swiss Federal Institute of Columbia University Omeros Corporation University of Texas at Houston Rentschler Biotechnologie GmbH Technology Lausanne Copernicus Therapeutics, Inc. Oregon Health and Science University University of Texas Health Science Center, University of Innsbruck Covance P2D, Inc. San Antonio University of Ulm United Arab Emirates Depomed, Inc. Parkinson’s and Movement Disorders University of Texas Southwestern University of Tuebingen United Arab Emirates University Emory University Center of Maryland Medical Center at Dallas University Hospital Goettingen United Kingdom FoldRx Pharmaceuticals, Inc. The Parkinson’s Institute and University of Virginia Greece Imperial College London Harvard University Clinical Center University of Washington Biomedical Research Foundation The Institute of Neurology The Institute for Neurodegenerative Disorders Philadelphia VA Medical Center University of Wisconsin, Madison Academy of Athens Phytopharm Intra-Cellular Therapies, Inc. ProteoTech, Inc. Vanderbilt University Proximagen Neuroscience Ltd. Intrexon Corporation Purdue University Washington University in St. Louis Iceland ReNeuron Group Plc Johns Hopkins University Rush University Weill Medical College of Cornell University deCode University of Cambridge Kaiser Permanente Sangamo BioSciences, Inc. Wyeth Pharmaceuticals University of Glasgow Link Medicine Corporation ShanaRx, Inc. Yale University University of London Zenobia Therapeutics, Inc MJFF ANNUAL REPORT 20 21 MJFF ANNUAL REPORT

2008 IN PHOTOS

Top Row, clockwise Top Row: from left: Actor Ryan Reynolds, MJFF Board Chair George Celebrity Chair of Team Prescott (left) and a Fox, high-fives member of his foursome Michael J. Fox at Mile 23 get ready to hit the green of Ryan’s $108,000 at Breaking PARkinson’s, ING NYC Marathon run. which in 2008 raised over $830,000 for Parkinson’s Middle Row, clockwise research. from left: Board member Al MJFF staffers Alison Glickman and wife Judy. Urkowitz (left) and Veronique Enos at the Michael J. Fox rocks out Parkinson’s Unity Walk. with The Who on the “Funny Thing” stage. Veronique Koch cycles for Team Fox. Board member Curtis Schenker and New York Anthanette Fields, one of Yankees shortstop Derek 130 Team Fox 2008 ING Jeter at “Funny Thing.” NYC Marathon runners who together raised $570,000 for MJFF. Bottom Row (l–r): Lily Safra, chairwoman of The Edmond J. Safra Middle Row (l –r): Foundation and MJFF MJFF Co-Founder Debi Board member, with Brooks and CEO Katie Michael J. Fox. Hood address 870 “Funny Thing” guests. MJFF staffer Jennifer Hagel with former attorney Michael J. Fox and general Janet Reno at the Tracy Pollan. Parkinson’s Unity Walk.

Bottom Row: Board member Ed The 2008 Team Fox ING Levy, son Matt Levy and NYC Marathon runners grandson Danny Levy at visit The Rachael Ray Breaking PARkinson’s. Show with Board member Woody Shackleton and his wife, Denise. MJFF ANNUAL REPORT 22 23 MJFF ANNUAL REPORT

2008 DONOR LISTING

The Michael J. Fox Foundation is humbled by, and deeply grateful for, This report lists those who supported us with significant contributions the incredible dedication of our friends and supporters. Your generosity in 2008. Also listed are the many friends and family members they allows us to continue doing whatever it takes to make Parkinson’s honored or memorialized through their donations. Their names remind a thing of the past. us that finding a cure has never been more urgent.

$20,000,000 or more $1,000,000 or more $500,000 or more THE EDMOND J. SAFRA CORE PROGRAMS The Brin Foundation Becky and Jack Benaroya Donny Deutsch* FOR PD RESEARCH In 2008, recognizing Elan Pharmaceuticals, Inc.** Einhorn Family Charitable Trust The Edmond J. Safra Foundation’s extraordinary $10,000,000 or more Anne and Burt Kaplan* Tracy Pollan and Michael J. Fox* commitment to our shared search for Chris Sullivan* Edmond J. Safra Foundation** Breaking PARkinson’s/Edwin A. Levy revolutionary treatments for Parkinson’s Kinetics Foundation** Great Investors’ Best Ideas $2,000,000 or more disease, MJFF named its core scientific Carolyn and Curtis Schenker** Foundation/Michele and EMD Serono programs in honor of the late philanthropist Shackleton Family* Shad Rowe Judith and George Prescott and humanitarian Edmond J. Safra. Mr. Safra’s Anne and Bernard Spitzer* and Family* Donor listing continues on page 24 devotion to this cause lives on with his beloved

wife, Lily, a member of the Board of The Michael *recognizes existing multi-year commitment J. Fox Foundation and, since her husband’s **recognizes new multi-year commitment passing, Chairwoman of The Edmond J. Safra Foundation.

MJFF BOARD APPEAL: CATALYZING INDUSTRY INVESTMENT IN PARKINSON’S DISEASE Speeding transformative The Edmond J. Safra Core Programs for treatments requires a creative strategy that goes beyond funding isolated projects in academic research labs. Increasing PD Research, focusing on historically under- industry engagement in pre-clinical therapeutic development is essential to bridging the gap between discovery and the funded stages of drug development, are: clinic. In 2006 the Foundation launched a three-year targeted initiative to deepen industry involvement in our efforts. Rapid Response Innovation Awards — MJFF is grateful for the remarkable dedication of our Board of Directors in helping us achieve this goal. With characteristic supporting groundbreaking Parkinson’s disease generosity and enthusiasm, members of the Board pledged over $10 million in seed funding. MJFF extends its heartfelt research in real-time. thanks to the following Board members, whose personal leadership, both financial and intellectual, continued to be vital to Target Validation — supporting rigorous our success in 2008 industry efforts: testing of early-stage discoveries to determine whether they are true targets for PD therapeutic development. Holly Andersen, MD, and Douglas Hirsch Judy and Al Glickman Tracy Pollan and Michael J. Fox Shanna and Jon Brooks Lisa Piazza and David B. Golub Judith and George Prescott and Family Clinical Intervention Awards — supporting Joyce and Barry Cohen John and Amy Griffin Foundation Michele and Shad Rowe clinical research toward new neuroprotective Donny Deutsch Ann and Skip Irving Edmond J. Safra Foundation treatments, improvements on existing therapies Einhorn Family Charitable Trust Marguerite and Morton M. Kondracke Carolyn and Curtis Schenker and treatments for unmet symptoms. Karen Finerman and Lawrence Golub Carolyne and Edwin A. Levy The Shackleton Family Fund Nelle and John Fortenberry Julie and Doug Ostrover Heidi and Daniel Spitzer Amy and Fred Weiss MJFF ANNUAL REPORT 24 2008 DONOR LISTING 2008 DONOR LISTING 25 MJFF ANNUAL REPORT

Donor listing $250,000 or more Prince Charitable Trusts Matthew Perry The Thomas and Jeanne Elmezzi The Peter Malo Family The Maya Romanoff Corporation Karin and Kenneth Travis Mutya Y. Badian continued from Anonymous Amy L. Robbins The Pimco Foundation Private Foundation Kathleen Kennedy and Royal Capital Managment Mr. W. B. Vollbracht Ms. B.E. Benaroya page 23 The Adams Foundation Wilkins Media Company, Inc. Rawley Foundation Lois and Richard England Family Frank Marshall Linda and Rick Rucker Remer and Donald Waguespack Robin Berman, MD, and Judy and Al Glickman Barbara and Michael Regan Foundation Soania and Arun Mathur Harriet Samuels Mary and Frank Walsh Ed Berman Lisa Piazza and David B. Golub* $25,000 or more The Robertson Foundation F. & J. S. Fund, Inc. Maverick Capital Charities Francesco Scattone Watch Entertainment, Inc. The Boston Foundation Amy and John Griffin Anonymous (4) Carolyn and Marc Rowan Fergeson, Skipper, Shaw, Keyser, Cynthia and Michael McConnell Lisa Rotmil and Alex Schmelzer Melvyn and Barbara Weiss Braude Foundation Julie and Doug Ostrover* AK Steel Foundation Pam and Jon Scarborough Baron & Tirabassi, P.A. Trish McEvoy The Steven B. Schonfeld Family Foundation, Inc. Peg and Jerry Brekke Parkinson’s Unity Walk Ammon Foundation Elizabeth and Scott Schefrin Richard H. Fitzgerald Cheryl and Robert McEwen Foundation Art Wrubel Bridgewater Associates, Inc. Robert Pritzker Peter and Irene Andrulis Charitable Mark Seliger Linda and Ron Galowich Dennis M. McIntosh Cheryl and David Schreiner Sara and Bill Wilkins Eugenia Brin R.B. Sellars Foundation, Inc. Lead Annuity Trust William and Jacqueline Shaw Danielle and David Ganek Jodi and Kenneth Meister Schwab Charitable Fund Joan B. Wilton Dave Burroughs Sutherland Family Estate Avenue Capital Group Family Foundation, Inc. Christen C. & Ben H. Garrett Patricia and Wallace Mersereau Scott Sibley Daniel Wolf Ms. Valerie A. DiFebo and Karen Pritzker and Michael Vlock Timothy and Michele Barakett David Shuman Family Foundation Leo Miller Family Foundation Elsa and Stanley Sidel Barbara and Stanley Zax Mr. James D. Byrne Foundation Chris and Julia Silbermann Pat and Charles Genuardi Alan B. & Barbara Hilary and Jerome Simon Robert Zemeckis Robert T. Chang $100,000 or more Bloomberg Solvay Pharmaceuticals, Inc. Nancy and Jonathan Glaser Mirken Foundation Mary and Robert Slaughter Jay Zukerkorn Steven Chrzanowski Virginia Brooks* Shanna and Jon Brooks Sopris Capital Advisors, LLC Sandra and Laurence Gluck Morgan Stanley Jean S. Smith Revocable Trust Paula Cleary Cantor Fitzgerald Buchalter Family Trust Henry Spector Diana Meehan and Gary David Bill Murray Sheila and Tripp Smith $5,000 or more Wendy and Victor Coleman Patricia and Jimmy Cayne Claire and Jason Capello Anne-Cecilie and Rob Speyer Goldberg Nike, Inc. Winthrop Smith Anonymous (3) Colorado Parkinson Foundation Joyce and Barry Cohen Ellen Hooker and Joseph Cassano The Jerry and Emily Spiegel Family Goldman, Sachs & Co. P Digital, Inc. Daisy and Paul Soros Ellen and Ken Aidekman The Daedalus Foundation Consolidated Anti-Aging Foundation Sonya and Dev Chodry Foundation Meg and Bennett Goodman Kimberly Williams-Paisley and Kristen and Matthew Spain Nonie and Larry Akman Fund of Norah and John Daly Karen Finerman and Steven A. and Alexandra M. Cohen Suwyn Family Foundation* The Grateful Foundation, Inc. Brad Paisley Corey Hajim and Jim Sperber the Community Foundation Linda Daly Lawrence Golub Foundation, Inc. Mildred E. Swanson Foundation Mr. and Mrs. Alan C. Greenberg Parkinson Association of Northern Elizabeth and Oliver Stanton for the National Capital Region Dark Trick Films Shannon and Mark L. Hart III Estate of Josephine M. Cretnik The Evelyn Teitelbaum Family Ellyn and Michael Greenspan California Sacramento The Steinberg Family Fund, Inc. Arlene and Alan Alda Katherine and Costa Darras Holly Andersen, MD, and John Crosland, Jr., Family Donor Charitable Remainder Unitrust Jennifer and Bud Gruenberg Valerie and Jeffrey Peltier Michael Steinberg Nancy Hausman and Jim Davidowitz Douglas Hirsch Advised Fund Vincent Tese Michelle Walter and Cyrus Hadidi Perelman Family Foundation Jean and Robert Stoessel Steve Alexander Jill Degen David and Barbara Hirschhorn Peter Cundill Maida and Ralph W. Tryon* Barbara and Ed Hajim Corky and Stephen Pollan Pamela and Jeffrey Swartz Mr. and Mrs. Robert A. Allison Daniela and Brian Delaney Foundation* Rachael Ray and John Cusimano Viacom International, Inc. Lynne and Harold Handler Jill and Mark Rachesky Mr. and Mrs. Doug Teitelbaum Susie and Charlie Anderson Gautam Dhingra Mr. and Mrs. David O. Jones DEARS Foundation, Inc. Amy and Fred Weiss Michael J. Harkins Elfrieda Remlinger Revocable Robert V. Tishman Izhar Armony Mark Dickstein M & T Trust and Foundation Norma and Charles Doering* Highbridge Capital Management Living Trust Joanne and Alfred P. Tobin Linda and Frank Ashe Dic-Wisco Farms, Incorporated Ronald O. Perelman Cheryl and Blair Effron $10,000 or more Armin & Esther Hirsch Foundation Carl and Ruth Shapiro Family Valerie K. Feigen and Steven Eisman Anonymous (7) Ashley and Charles Holzer Foundation Entertainment Industry Foundation Air Dimension, Inc. The Howard Family Charitable Fund Heidi and Daniel Spitzer The Ettleman Family Fund Jack and Sylvia Altman Foundation Imperial Capital, LLC Lisa and Philip Falcone The Atticus Trust ITSource Technology The Michael J. Fox Foundation is grateful for the generosity and foresight $50,000 or more Kathryn and Oliver Gill Band From TV, LLC Patricia Jehle THE GROVE CIRCLE FOR PLANNED GIVING Anonymous (3) Jay Goldman Estate of Lisa Susan Baricelli-Kureen Patti and Lee Johnson of its friends who support the Foundation through bequests and other planned gifts. In 2007 Andrew S. Grove, co-founder Anonymous Fund at The Silicon Stephanie and Robert Goldstein Rosemary Beach Foundation, Inc. Eleanor Frances Nelson Jordan of technology giant Intel and special advisor to the Foundation, informed us of his intention to bequeath a portion of his Valley Community Foundation Julia and Joel Greenblatt Melissa E. Benzuly Steven Jordan estate, up to $40 million, to establish The Grove Circle, a planned giving society to formally recognize the commitment of If you have Bachman-Strauss Dystonia and Marc Haas Foundation Christina Bloom Drs. Julie and Scott Kalniz made estate Parkinson Foundation, Inc. Mr. and Mrs. John S. Hager* Benjamin Bram Katzenberg Family Trust these legacy givers. plans that Stephen and Carolyn Chase Thomas K. & Yvonne G. Hanes Joan DeHovitz and Aaron Braun The Keyser Family We thank the following donors of estate and other planned gifts, whom we now honor as members of The Grove Circle: CJM Foundation Charitable Remainder Trust The Andrew Nagel and Dolores E. Kossak Trust include MJFF Close To A Cure Susan and Kim Henry David Brodsky Fund The George Kress Foundation, Inc. and would like Deutsche Bank Securities, Inc. Robert and Marjorie Hirschhorn Charles Burnett Rachel and Amar Kuchinad Anonymous (5) Estate of Helen Hoskin The Donald and Martha B. Geibel Trust Rose Krieger to be listed as Dr. Eva Andersson-Dubin and Tracey and Michael Hisler William O. Burnett Foundation Kathy and Michael J. Lewis Richard Belman Estate of John Christopher Kimmey Juan Griego Sally and Andrew Lorenz a member of Glenn Dubin David C. Horn Stephanie and Wayne Caron Mrs. Wendy Gimbel and Lorri Boetto Estate of Dolores E. Kossak The Frederick W., Norma G., and The Edmund Ernst McClure Trust The Grove Circle, Packy Jones, Ilan Adika & Melinda and Ron Insana Donna and Jake Carpenter Mr. Douglas S. Liebhafsky Virginia Brooks Estate of Louis Krieger Janet L. Grill Family Estelle Randolph Jones Trading The Rona Jaffe Foundation Susan and Nicholas Carter The Litwin Foundation Jock Casasus Estate of Raymond H. Lake Endowment Fund Judy Reidel please call Morris Kaplan and Delores Jet Capital Investors LP Coach, Inc. The Lobster House on Cal Chadwick Estate of Byron Mavrelis Andrew S. Grove The Elfrieda Remlinger Revocable Karen Leies at Kohl Kaplan* Sonia and Paul T. Jones Judith and Hugh E. Corrigan III Fisherman’s Wharf Frederick C. Colton Estate of Geraldine McMillan Thomas K. & Yvonne G. Hanes Living Trust (212) 509-0995, Khronos LLC Christa Miller and William Lawrence Larry and Anne Davis Amalia and Peter H. Lucas Anne and Larry Davis Estate of May Moore Charitable Remainder Trust Thomas Sabourin ext. 269. Carolyne and Edwin Levy Jennifer and Marc Lipschultz DCI Group, LLC Admiral and Mrs. Thomas Lynch Estate of Lisa Susan Baricelli-Kureen Estate of Sidney Kanz Morgan Richard Henriksen Henry F. Spector Joella and John Lykouretzos Margaret Munzer Loeb and Vincent and Rosemarie DiPatre’s Tami and Fredric Mack Estate of Ruth Carter Estate of Don and Ruth Palmer Lee Herman Dorothy Strauss McDermott/McManus/ Daniel Loeb Charitable Fund Julie and William Macklowe Estate of Alma Chitwood Estate of Jean Patton Mary Hopkins The Sutherland Family Bloom Family Estate of Byron Mavrelis Mr. and Mrs. Edward J. Dobbs The MacMillan Family Foundation Estate of Diane Mae Clark Estate of Melvin Rauch The Hoover Family Charitable Elizabeth H. Weinraub Norman A. Merollis Estate of Geraldine M. McMillan Corinne L. Dodero Trust for the Robert F. Maguire Estate of Josephine M. Cretnik Estate of Marjorie Richards Remainder Trust The Dotha S. Welbourn Charities Trust The Miller Family Foundation Catherine and John T. Morse Arts & Sciences Janet and Tim Maher Estate of Beryll Deming Estate of Eileen R. Salter Judy and Charles A. Huss The Charles C. White Revocable Trust Novartis Pharmaceuticals Donna and Gary Naftalis Craig Effron and Company Mail-Archive, Inc. Estate of Marjory S. Fellman Janet and Robert B. Ettleman Eleanor Frances Nelson Jordan Kathryn P. Wright Pershing Square Capital Managment Park Foundation Judy and Jamie Dimon Make It Possible Foundation Estate of Rafael J. Gonzalez Jeff Evans The Jerry Katz Trust Yacuone Living Trust

*recognizes existing multi-year commitment **recognizes new multi-year commitment MJFF ANNUAL REPORT 26 2008 DONOR LISTING 2008 DONOR LISTING 27 MJFF ANNUAL REPORT

$5,000 or more (continued) Esther and David Laventhol Rucker Candy Foundation Avon Products, Inc. Amelia Feinberg Mary Hopkins Julie and Don Morton Natalie and Kent Shinback Susan and John H. Dobbs, Sr. Marc and Linda Lawrence Perri Peltz and Eric Ruttenberg Anthony Baer Amanda and Michael Feinsod Harriet Hubbard Lou Moskowitz Glen and Amy Siegel Greg Drumheller Family Trust Jeff and Joanne Schimelman The Arnold F. Baggins Scott D. Ferguson Judith and Charles Huss Stephen G. Moyer Rita Sklar Joel Ehrenkranz Mr. Harrison T. LeFrak Schonfeld Fund Advisors Foundation, Inc. Fifth Street Capital LLC I Do Foundation Kathleen Mullarkey Maureen and Glen Smith The Evslin Family Foundation Lehman Brothers Michelle Ores and Charles Schorin Steven M. Ball Bill Fischer The Barbara and Alan Iselin Beth and James Kevin Murray Sydell and Ira Smith Quinn and Bryan Ezralow The Leibowitz & Greenway Family Mr. and Mrs. Lewis Schott Bank of America Sandy Krause and Bill Fitzgerald Family Foundation, Inc. Buz Nathanson Jude and Joseph Smith Richard Fiesinger Charitable Foundation Meryl and Jeff Schwartz Paul C. Baria Debby and Louis Flancbaum Josflo Corporation Alexandra and Michael Nolan Will & Jada Smith Michele and Drew Figdor Janet Lewinter Signature Bank Barbara S. Baxter Rayma M. Flint Sheryl and Tony Jedlinski Northrop Custom Metal, LLC Family Foundation Firman Fund Licensing Executives Society USA Fiona and Alan Silver Bayview Foundation Evelyn and Tom Fowler The Jewish Community Federation Ohio Parkinson Foundation SNAIDERO USA Nelle and John Fortenberry and Canada, Inc. Mr. Sanford Sirulnick Becker Trading Company The Connie Frank Foundation of Cleveland Northeast Region Sound Sight Technologies, Inc. Alan D. Fragen Holly S. Lipton David Sjolund Cecilia Benner Debbie and Brent Fredberg Jewish Federation of Masahiro Oishi Charline and Lou Spain Irene and David French Kim Staller and Joseph Macari Randy Slifka Philanthropic Fund Carolyn and Donald Berger Mark Frey Metropolitan Chicago John E. and Deborah P. Osborn Spriggs & Hollingsworth Julianne Moore and Bart Freundlich Ellen and Mike Maguire Tamara and Adam Sloan Nelson Blair Harry A. Friedberg The Joelson Foundation Mary Anne and Jim Ostrenga Darcy Stacom Andrew and Brooke Friedman Mary and Robert Mandell Phyllis and Rick Slocum Dr. Maxwell L. & Florence C. Joyce Frost Carole and Frederick Johnson Elizabeth and Robert Owens Michael Stein Joyce and Clifford Friedman Rita and Michael Markel Judith Smolin Blumenreich Foundation Chris Furie Harry Johnson The Pacer Foundation Susan and Robert Stephens Renee Furr Carol and Dennis Markos Trygve A. Solberg Brandes Investment Partners, L.P. Linda and Sidney Furie Amy S. Jones Parkinson’s Resources of Oregon Margaret P. Stevenson Foundation Deborah and Donald Gill Mayer Family Foundation Sony Corporation of America James H. Breay Lori and Simon Furie Josflo Corporation Doris and Tom Parry Judy and Steven Straub Global Impact The J. Robb Mayo Charitable Trust Melanie and Thomas Staggs The Eli and Edythe L. Broad GE Commercial Financial The Sidney & Pearl Kalikow Foundation John Patton Stupell Foundation, Inc. Lisanne and Howard Godnick Pamela and Robert McCabe Mr. and Mrs. Erwin P. Staller Foundation Services, Inc. Beth and Charles Kaplanek Amanda and Jonathan Paul Sundance Running Club Goldman Sachs Gives The Edmund Ernst McClure Trust Stanko Stojkovic and Family Ms. Leila Kamal and Mr. Andrew The Gerson Family Jay Kasner Virginia F. Pentecost Brett and Daniel Sundheim Agnes Gooch James S. McKarns, CIH, CSP Carol and Jim Storm Brockway Gerson & Gerson, Inc. The Katz Foundation Amy and Joseph Perella Jane and Scott Sussman Brian Gottlieb Mary Meeker Jennifer and John Streit Sara and Ivan Brooks Mike Ginsberg Rosalind and Marvin Kay Deveaux and Shane Philpot Dixie Swanson Bonnie and Tom Grace Robert A. Mileti Talfrank, Inc. The Elsie A. Brown Fund, Inc. Edward W. Gjertsen Michael H. Kelson Laurie and Asher Platt Steven Swarzman Wally and Charlie Graham Mr. and Mrs. Michael G. Miller Tamkin Foundation, Inc. Nina and Joe Brown Family Nancy and Jonathan Glaser Harris and Eliza Kempner Fund Sylvia L. Polen Marilyn and Lynn Thompson Marisa and Edward Green Scott M. Murray Teva Neuroscience Philanthropic Fund The Glen Oaks Philanthropic Fund Mary and Richard Ketchum Judith Belzer and Michael K. Pollan Kent M. Thornbrugh The William M. Green Foundation Tracy and Larry Nagler The Thrasher Family Mr. and Mrs. James T. Buckley Laurie and Jeffrey Goldberger Patricia Stonesifer and Michael Colette Porcelli Alice and Tom Tisch Laura and William A. Gruy Bruce Nash Entertainment Andrew H. & Ann R. Tisch Foundation Phyllis Richman and Bob Burton Victoria T. Baker Graboys Kinsley Portland General Electric Company Titan Outdoor, LLC Gayle Halpin Jack Nash Turner Family Foundation Patrick Campbell David and Jill Graham Elaine Kranich Dawn and Patrick Prescott Gail and Richard Ullman Kathy Harris Newman’s Own Foundation, Inc. Mr. and Mrs. Charles Tyler Jason Capone Alison and Andrew Gratz Kraysol Investments Prescott Family Foundation United Talent Agency Valerie A. Hughes and Newmark Knight Frank The Ullmann Family Foundation Ruth Jones Casey Foundation Daniel Gray Dr. and Mrs. Lawrence E. Lee Marla and Dean Provost S. Wil VanLoh Jr. Stephen D. Hays Kim and Richard Nicely United Talent Agency Linda and Bernard Chalfin The Greater Cincinnati Foundation Lehman Family Charitable Giving Larry F. Randall The Wagner Family Foundation Morris Hazan Charitable Foundation Joyce and Bill Niles Gopalan and Santhi Vasudevan Charina Foundation, Inc. Sharon and Roy Greif Fund The Ravet Family Fund of the Jewish Charles E. Wainhouse Richard E. Henriksen Diane M. Pattee Wachovia Securities Rita and Herbert Chestler Michele and Martin Greenberg Giselle and Michael Lerch Community Foundation I. Waldbaum Family Foundation Benjamin and Jessica Hoyer Barbara H. Pekow The Walsh Family J. Dawn Christman Sandi and Ken Greenblatt Wallace R. and Bernice E. Leslie Red Bar & Restaurant Nancy and George Walker Anne and Thomas J. Hubbard Peggy Pellak Mary and Jack Ward Stacy and Richard Clark Greenlight Foundation, Inc. Memorial Fund The Richie-Madden Children’s Norma and Ed Weinman ING The Pevaroff Cohn Family Foundation Wenner Media LLC Stuart Clifton Donald E. Greenway Madelyn and Richard Levy Foundation The Roberta and Allan Weissglass International Creative Management Shlomit Piatetski-Shapiro The Harold Wetterberg Foundation Diana H. Newman and Corene Griffin Charitable Fund The Lichtenstein Foundation, Inc. The Philip W. Riskin Charitable Foundation Ann and Skip Irving James and Virginia Pitts Carole and Rick Wiederhorn Isaac D. Corré Amy Lauren Gross Light Of Day Foundation, Inc. Foundation Sharon and James Welty IXIS North America, Inc. Julie Turaj and Robert Pohly Dr. and Mrs. Stan Williams Michael Costa Vicki and Michael Gross The Jack R. Linsky Foundation Carolyn and Charles Robins Jan and Eddie Woods JNK Securities Corp. Lea and Barry Porter Mr. L.B. Windham Lois and Marvin Cowan GVI Property Management Annette P. Lintz Larry D. Roi The College of Wooster Lisa N. Johnson Ms. Jeanne F. Coleman and Winthrop Lodge of Elks Mack H. Curtis Andrea and John Hampshire Magic Media, Inc. Michael R. Romanowski Jennifer and David Wroan Larry Jones Mr. Lawrence F. Portnoy Ziffren Brittenham Branca Fischer D.A. Davidson & Co. Judy and Joseph Harding John Magnuson Allen Rosenberg Barbara and Leon Wulfe Patrick J. Jordan Michael F. Price Gilbert-Lurie Stiffelman Cook Mary Danakas Harper The Chris & Melody Malachowsky Barbara Rosenfeld Alyssa and Larry Yavner Ellen Francesca Judge The William L. Price Charitable Johnson Lande & Wolf, LLP Osteria Da Nino Adele and Mark L. Hart Jr. Family Foundation Lawrence Ruben Donald A. Young Joy and Eric Kaye Foundation Ruth Zinar Kimberly A. Davis Kristy and Rob Harteveldt Kuldeep Malkani Gary Rubin Mr. and Mrs. Wayne R. Zdenek Bonny, Andrew and Isaiah Keller Bradley L. Radoff Davis Selected Advisers, L.P. Teri Hatcher Matthew H. Mark Brad Ruderman The Jacquelyn & Gregory Zehner Nancy Kitay Galdi Harley and Robert Raiff $2,500 or more Elizabeth R. Miller and Daniel Hedlund Heather J. Marsh Edward Sacks Foundation Bonnie and Bradford Klein Linda and Richard Reiss Anonymous (5) James G. Dinan Jami and Nikolaus Heidegger Verne R. Mason Abby and Steve Sakwa Zimmerman Heimbach Foundation Robert E. Klein Jennifer Saul and Stephen Rich Access Industries, Inc. Jason P. DiNapoli-1st Century Bank Sheila and Jonathan Herr John and Maude Matouk Kenneth Salling Phoebe Cates and Kevin Kline Robbins Family Fund Mary and Edward Allen Bosko Djordjevic Bill Herzig Charitable Foundation James and Janet Sammer $1,000 or more The Knauer Family Carmen Frank and Mark Robbins Jean and Harold Allen DOT Federal Credit Union Bernadine Tosetti Hines John L. McHugh Foundation, Inc. Vik and Margarita Sawhney Anonymous (17) Michael A. Kolodny John Rogers/Whyte Hirschboeck Donald Allman Kenneth Douglas Foundation Foundation Michael B. McMahan Joshua Schechter Nancy and Colman Abbe Marguerite and Morton M. Kondracke Dudek Government Affairs LLC Joan and Lawrence Altman Julie and Matthew Edmonds James Ho McKesson Corp. Jennifer Schneck The Gerald Abell Foundation John & Evelyn Kossak Foundation, Inc. Joshua Rosman American International Group, Inc. Marty and Dale Ehrenreich Judith E. Tschirgi and Steven J. Hoch Barb and Terry Meguid Richard R. Schumann Iris Aberbach Nyssa and Bill Kourakos Hilary Geary and Wilbur Ross American Parkinson Disease Bruce W. Elder James Holmes Sue and Fred Menowitz Ralph Schwartz Jeani Adams Christina and Barry Kringstein Eric Rothfeld Association, Georgia Chapter Nell Everman Samuel and Hannah Holzman Trust John Metzger Gretta and Barry Seidel Carol and David Adler Land Rover North Point Shani and Doug Rothschild The Stanley and Blanche Ash Susan and C. Scott Fahey Katie and Aaron Hood The Ken and Julie The Seinfeld Family Foundation Ashley and KC Agrelius Mr. and Mrs. Swayne Latham Steven G. Rubenstein Foundation Paul D. Farrell Judith and Michael Hooffstetter Moelis Foundation Megan F. Shackleton Brenda and Robert Aiken MJFF ANNUAL REPORT 28 2008 DONOR LISTING 2008 DONOR LISTING 29 MJFF ANNUAL REPORT

$1,000 or more (continued) Nancy and John Bertino Patricia and Alfred Byrnes Cranfill, Summer, & Hartzog, LLP Jody Eldredge Shirley Gleich James and Marjorie Herald Kristen Snow and Fred Jones Margot and Ariel Aisiks Brian Moynihan and Susan Berry Laurie and Ryan Cahill Attorneys at Law Merrill and R. Park Ellis Robert and Lois Glick Lawrence Herman The Grace Jones Richardson Trust Lawrence Akin Charitable Fund The Harman Cain Family of Don Crisup Janet Elsbach Jeff Glickman Candice and Michael Herman Rudolph and Mildred David Alcaro Jo Anne and David Bescherer Family Foundation Greg Croll Emmanuel, Sheppard and Condon Janis and Alan Goldberg Debra Hernberg Joseph Foundation Geraldine and Harold Alden The Bickel Family Foundation Carol S. Callahan Gerard M Cronin, Jr. Rodney English Betty and Eliot Goldwarg Jim D. Herrgesell Sheryl Josephson Jeanie M. Alfuhaid Les Bider Barbara and Roger Calvert Crowley Family Foundation Joann and Wayne English Saul Goldwarg High Five Foundation Patsy and Al Kahn Michelle Alifanz Craig Bierko Len Camber Grantor Trust Cumberland Community Episcopal Church Women of Christ Arnold J. Golub, PhD Linda K. Hinkle Claudia J. Kahn All Area Services Andrea Billhardt Cambridge Area Parkinson Foundation, Inc. Church, Frederica Leslie Finerman and Sean Goodrich Laurie and Matt Hogan Mary and Doug Kahn Nancy and Myron Allen Jo-Anne Williams and Support Organization Darlene Cummins Howard Epstein Sandra and Thomas Allen Gookin Carron Sherry and Richard Hogan Edward Kalikow Amy Albright Richard Bilotti Can-Do Cundall Striper Millard M. Cummins Drew Ertman Collette Morrissey and Greg Holden Stephen F. Kaney The Donald C. and Norma Ian Birch Tournament Richard Curtis Judith and Irving Evall R. Kenneth Gordon Russ Holmes Rikki and Barry Kaplan (Klug-French) Allyn Fund Jack and Karen Bishop Louise and Larry Canterbury William Curtis Terri and Bruce Evans Elizabeth Gotlieb Jim and Cheryl Holt Carol G. Kaplan AlphaNet, Inc. Joann M. Bisto CapitalSpring, LLC Louis Dahan Marlou and Lendon Everson The Gould-Shenfeld The Homme Family & QOTSA Ruth and Jesse Karter Diane and Bill Alt Janesy and Roland Blankenhorn Ann and Jeff Caplan Jane Ploessl Dallam Doron Ezickson Family Foundation Honeywell Hometown Solutions Karuna Foundation Alva Builders, Inc. Carol and Jim Blann Elaine R. Caplow Linda Daly Maggie Fairchild David Goyer Janie Hoover Howard Kaskel American Agricultural Insurance Betty and Ray Blansett The Carmen Foundation Christine and James Dart Stephen E. Farris Stephen L. Graessle Keith A. Hoover Esther and Harold Kassab Company Elaine J. Block Ian T. Carnathan Daryanani & Bland PC Fasnacht Family Foundation Graff Valve and Fittings Company Rosemarie Hovey The Jerry Katz Trust Sue and Dana Anderson Judith C. Block Barbara Carpenter The Solomon D. and Victoria Bunny and Sy Feigenbaum Camille E. Granato Alexis Howard Margie Katz Anheuser Busch, Inc. Kristie and Steven Block Ms. Barbara E. Carr and Family David Foundation Eric Fellner Erica and Kenneth Grau Jane T. Howard-Johnson Andrea Kay Richard P. Anthony Mary Lou Bloede Agnes G. Carter Rabbi Joshua Michael Davidson Sr. Erika and Spike Feresten The George & Reva Graziadio Howard Howe Dorothy and James Kay Lynda and David Archer Sandi and Jerry Bloomberg Jock Casasus Rabbi’s Discretionary Fund Bruce Ferguson Foundation Ann Huber Nancy and Mitchell Kaye Dane Arden John and Myrna Blume Dawn and Rocky Caullwine Mona and Gary Davis Clara and Vince Ferraro Donald Green Anthony P. Hughes Milly and Robert Kayyem Jennie Armstrong Boar’s Head Brand Cassametta CDW Corporation Deeds Foundation, Inc. David Fialkow Theodora and Robert S. Greenbaum Jack W. & Kathleen J. Hugus John W. Keith Jody and John Arnhold Provisions, Inc. Centre Reinsurance Michael De Jong Nathan Fillion Eric Greenberg Foundation Seow K. Kek Thay AST Capital Trust Company of Charles Bockoff Bev and Cal Chadwick David Deibel Laurine Fillo Sheila Greenberg The Huisking Foundation, Inc. Katrina and Pat Kelley Delaware Mr. and Mrs. Hendricus Bocxe Carol Chase Janet Delaney Norman Findling Christopher H. Greendale Derris and John Humphrey Denise E. Kemble August Benefits, Inc. Michael J. Borgerding The Cherry Picker Foundation Michael D. Del Giudice The Firm Foundation Construction Sherwin Greenwald Mr. and Mrs. Ronald E. Hunt James A. Kendall Aumund Corporation Jean C. Borre S. Chitis Denice Dequinzio Company, Inc. Clark Grimm Mary Jo and Mitch Hurwitz Arline and Robert Kennedy Austin Community Foundation Nicholas Botta Christian Mission Concerns of Denise DeShane Carol Fisch Anthony Guagliano Jill and Stuart Hurwitz The Kerdan Group The Austin Family Fund David Boutry Tennessee, Inc. Linda and Scott DeViney Nick Fitzpatrick Helen Guishard Holly and Thomas Huth Pam and Archie Kerr John and Kathy Bahas Kathryn Bowes John W. Christopher Charles Diamond Cmdr. Richard A. Flak Jeffrey R. Gural Hypno Design, Incorporated Jim & Irene Kerr and Family Lori Pollan and Allan Bahn Joel Boyarsky Chubb Corporation Jerry Diamondstein Kirby and Glenn Floyd Stephen Haberkorn Indianapolis Power & Light Company Kind Family Trust Amy Baker Norm and Linda Boyer C.J.V. Holding Corp Harriet Ford Dickenson Foundation Brandon Fortune Ginger and Larry Hahn David B. Ingrey Kathleen R. King Pam and Jesse Baker Ethan S. Bradley Erin E. Clark Richard Dickstein Fox Family Foundation Halperin Foundation Inn At Quogue LLC Patricia King Cynthia Berman and Howard I. Baker Zach Braff Claremore Club, Inc. Lisa and James Dobbs Robert A. Frazier Joseph Haller IPT, LLC Kings Pharmacy & Surgical Faye and Julian Baker The Brandsma Family Foundation Roxan and Doug Clausen Betty and Robert Dorn Freedom High School Rodney Hamilton Valerie Fronstin-Atkins and Enis and John Kingsley Jr. Thelma and Raymond Balbes Lynn A. Brody Claw and Dagger William Dornette Bruce Freeman Rita Wilson and Tom Hanks Robert Iverson Kinsell, Newscomb & De Dios, Inc. Leslie and Buck Balkind Ellen and Peter Brody Judy and George Clute Jeremiah Driansky Sharon N. Freytag Susan and Richard Hare Family The Jackman Family Foundation Mary and Clarence Kipps Reneé Ball Deborah W. and Jeffrey Brooks Louise and Thomas Coffey Hillel Drazin Anne and Malcolm Friddell Foundation Tracey Jacobs Margie and Weldon Kirby Shirley and John Bandy Joy and Robert Brorsen Suzanne and Michael Cohen James Driscoll Lauren Landau Fried The Harnisch Foundation Kathy and Mitchell Jacobson Rebecca A. Kirk Bank of Montreal John F. Brown Mr. and Mrs. S. Michael Cohen Margaret J. Du Frayne Jacqueline L. Friedman David A. Harris Colleen and Gene Jacobus Kitchen & Associates Matthew D. Bantly Michael Brown Perry Cohen and Rosalie Mandelbaum James M. DuBois Edna Frigo Sharon Harrison John R. Jagar Audrey and Leonard Kleiman Bard Employees Federal Credit Union Diana Browner Eve Collen-Cohn Lisa and Raymond Dubois Cynthia and John Fruhwirth Jeremiah T. Hart Samay Jain Kevin Koch Kerri and Richard Bartlett Keith N. Browning Eleanor Collier and Family Richard Fullerton Thomas Hart Dr. Debra Jaliman David Kramer Michael P. Bartsch Family Foundation Tracey and Adam Collins Dorothy Dupper Judy and Philip Gage Cynthia and John Harter Rodney K. Janson Clyde and Lisa Krogh Kathleen C. Bassi Brumberger Foundation, Inc. Ms. Betsy Collins and Duprey Investments Robert Gallagher Katie and Philip Hartgerink Susan and James Jaqua Kathryn A. Kronick The Baupost Group, LLC Margie and Dudley Brundage Mr. Thomas P. Collins Marsha and Anthony Durniak Patricia and Lawrence Gallaway Robert B. Haserot Frances and Arthur Jenkins Fridelle T. Krug Beach Equities Paul Brundage Competition Corvette Association, Mary and Michael Dykema Irene Kim and Richard Gampell Ted Hatch Kathleen M. Jenkins David Kurti Beall Consulting Services, Ltd. Tracy and Paul Buckley Incorporated Eagle Mountain Real Estate Suzanne W. Garnett June M. Haverly Nick Jensen Lake Pizza and Restaurant Karen Bechtel Christine Bulawa Pamela and Scott Condron Stanley Ebner Gemini Elementary School Sue Hayhow Jewelry Fashions, Inc. Judy and Joseph La Mastra John C. Beck Sandra Bullock The Jim and Barbara Conen Carole and David Ebner Beth and David Genuardi Hearst Magazines John Hancock Financial Services Lambert Family Foundation Don C. Bedell Laura Kang and Paul Burkhead Charitable Fund The Robert & Gail Edelstein Genworth Foundation Mary F. Heinrich Carol Johnson Betsy and Branch Lane Dr. Holley A. Belch Linda K. Burrows Michael J. Connell Foundation Joan L. Germany Judy and Robert Heiser Erik Johnson Linda and Jules Lane Barbara and Peter Benedek Allen Burry John C. Conwell Liz and Stephen Edwards Al Gerk Hekemian & Co., Inc. Deanne and Eric Johnson Chriscinda and Fabian Lange Raymond Benner Living Trust Jennifer Burton Gordon Cooley Nancy and Steve Einhorn Karin Giffney Carol and Mitchell Held Koren and Joe Johnson Mary Lou and Bill Lange Steven R. Berger Eugenia and George Burylo Amanda B. Coombs Daniel Einhorn Philip F. Gilligan Rachelle Helfand Barbara and Mike Johnson Diane and Jerome Lapham Pearl Berger BWD Group, LLC Katherine and John T. Copeland Mitzi & Warren Eisenberg Family Alvin and Rose Gindel Foundation Betty and Irwin Helford Laurel Johnson Smith and Kevin Smith Patti Larkins James Berkus Anne and Russell Byers Cowen Services Company, LLC Foundation Vicky Gjelaj Trevor L. Henson Amelia Jones Feinberg Sue and Tom Larsen MJFF ANNUAL REPORT 30 2008 DONOR LISTING 2008 DONOR LISTING 31 MJFF ANNUAL REPORT

$1,000 or more (continued) Mariner Advisory Group, LLC Mariann and Carl Morales Faye Pender The Mark Ross Foundation Linda and Bob Sims Jill Tracy West Coast Fire Protection, Chris Larson Marlette Family Foundation George Mori Arthur J. Peponis Family Fund Georgina and Alan Rothenberg David Sims TradeBytes Data Corp. Incorporated Pamela and Erik Larson Lea Marshiano Susan Morrow Consuelo C. Perez Stuart Rothstein Aaron Sirulnick Jean M. Trainor Mr. and Mrs. Avery B. Whidden Mary and Robert Larson Buddy and Dorothy Martin Foundation Brian Moynihan & Susan Berry The Perlmutter Family Foundation The Rubin Family Foundation Bridget Sisson John Trani Whitlock & Associates The Abe and Frances Lastfogel Roxanne and Rocco Martino Charitable Fund Lisa and Richard Perry Susan Rubino Marci and William Slepoy Traub-Brittan Family Foundation Mary and Rick Whiting Foundation Diane and Richard Mason Mur-Lee’s Mens Shop Julie Persily Natalie Rule Cliff Sloan Ann and Bill Trembler Mary Whitworth Jan and Fred Laughlin Bruno A. Massaro Greg Murphy Sandra and Norman Pessin Connie and William Rumold Robin and David Small Loren Tripp David C. Wiener & Company Laurel Conqueror 451 Susan Matthews Marybeth R. Murphy Joan Petty Amy M. Russell Lisa and Brian Smith Linda B. Trugman Donald E. Will Blanche and Irving Laurie Foundation Joy and Tom Mauer Mary and Warren Myer Alfred Phillips Betty and Kenneth Russell Laurel Johnson Smith and Kevin Smith Clifford Tune Montel Williams The Lautenberg Foundation Robert W. May Robert D. Nankervis David Phillips Marilyn and John Russell Byrom J. and Victoria M. Smith Family TRW Systems Federal David L. Willis Jeffrey LeBlanc Maxx Properties National City Bank Physicians World Knowledgepoint Sarah Gleacher and Kenneth Ryan Charity Fund Credit Union Bruce Wilson Phillip E. Ledin Susan and Scott McBride Michael Naumann 360 Group, LLC Ramy Saad Lynn Solky Jane and Wat Tyler Michael D. Wing James E. Lee Anne N. McClure Julie and Sean Nazareth Pillsbury Winthrop Shaw Pittman LLP Thomas J. Sabourin Lisa, Jared, Jake, and Mitch Solomon Miller H. Ullmann Daniel Wistran Joohyung Lee Dorothy E. McCormack Margaret and LeRoy B. Negus PMC Corp. DBA Vertigo Leslie Sack Nicholas Sordoni Thomas Ullrich Joel S. Wojnilower Juanita and Joseph Leff Docie and Larry McCormick Clarke Nelson Gloria W. Polis Mildred and John Sakosits Sparton Technology Corp. Jeanne Usonis Wolters Klumer Health Jill L. Leinbach R. Cathleen Cox McFarlane Charitable Linda Nelson Ann and Peter Pollack Cecilia and Rafael Saladrigas Rik Spier Katherine and James Utt Edna Woods Cynthia and Francis Leizear Foundation, Inc. Richard P. and Faye Nespola Elaine and Henry Pope, Jr. Frederic V. Salerno Lynne and Eric Spillman Ricardo Vallieres Florence and Robert Wooley Debra Perala and Robert Lemon Marjorie & McGahren Foundation Charitable Foundation Carol A. Porter Cynthia Salzhauer Justin Spitzer Victoria and Walter Van Den Burg WPP Group USA, Incorporated Gil & Regina Letrondo & Family Helen M. McGinn Net Work For Donations Marc Porter Dave Sankey Karen Spring Loren K. Vanderslik Gerald Wright John Leupp Jane and Ray McGowan Sabine Neumann Elizabeth and Calston Christian Alan Sarokhan Robert Stanlake Vector Search Group Yale Capital Corporation Martha K. Levin Matthew B. McGrath Douglas Newton Preston Family Fund Linda Sawyer Simon Stanlake Nicole and Michael Vermut Steven B. Yankelevitz The Richard L. Levin Family Chris and Linda McKenney Kevin T. Nguyen-Tu Tony Proctor Kenneth Schaner Darren Statt Vern Clark & Associates Fannye Yates Foundation Nancy A. McNamara Kimberly and Thomas Nicastri Ann Purcell Holly and Carl Schaus Janice and Dennis Steindler Marcy and Tom Vogel Wanda and Charles Young Abigail and Anton Levy Catherine and John McWilliams Jeffrey Nobel Sandra and Darrel Quick Mr. and Mrs. Mitchell S. Schecter Steiner Sports Memorabilia Voluptuous Kitchenware Peggy Kratz and James Young Edward and Jami Levy Foundation Lisa and Christian Meagher Vincent Nocerino Dr. and Mrs. Bernard N. Raasch David Schelzi Jack Stephenson Storytelling, Inc. The Zannettis Family Joseph Levy MEDLINKS LLC Janet A. Norris Michael Racine The Schiff Foundation Liz and Emanuel Stern Mieke and Ad Vos Mary Ann and Gene Zink We have made Anne Lewis Medtronic, Incorporated Virginia W. Norris Martha and Emil Ragones Christa and Calvin Schmidt Allison and Leonard Stern Wachovia Daina Zivarts a concerted Fred Limbach Christopher Mellen Family Fund Debrorah and David North Robin and Jeffrey Raish Lauren and Patrick Scott Laura D. Stewart The Peggy & Ellis Wachs Family Denice and Tom Zucca Karen and Mark Limbird Annette Merle-Smith Nancy Nowick-Kauk Lisa and Jim Ramsay The Jean and Thomas Schreiber Elizabeth and Donald Stinett Foundation effort to Lincoln Elementary Betty and Robert Mero The Deryck G. Nuckton Living Trust Karen L. Ramsey Philanthropic Fund Marie Strebel Debbie Wackel accurately CSJJJ Litt Foundation Arlene and Robert Merson Patricia and Richard Nye Adam Ratica Mary and Richard Schuster Martin Stuart Wagner Braunsberg Family list all donors Linda and Robert Livingston Patti and Jim Messenger Ruby and Jack Obenauer Robert J. Reby & Co., Inc. Susan Schutzman Peggy Sturman Foundation, Inc. of significant Adele F. Loeb Caryn Messinger Robert C. Oberheide Amanda Reed Teresa and Daniel Schwartz Sugarbush Chuck Wallace contributions Loewenstern Foundation John Metzger Anita O’Boyle The Reichert Foundation Eileen Scott Vivian and Charles Sukenik Dr. Stacey Wallach and Deborah and Jim Long Elizabeth Dinkel and Aaron Meyerson Joy Graustark and Larry Oesterich Mrs. Rose Remin and Family Shereta Seelig Susanne and Timothy Sullivan Mr. Joshua L. Wallach in 2008. Long Beach Memorial Medical Center Middle Bay Charitable Foundation Brenda and Budge Offer Jack Remnet The Selkowitz Family Foundation Sures/Ward Family Trust Penny and John Wallerstein Antone and Deborah Lott Fran Middleman Kit and Roger Olen Kimberly J. Rendleman Kek Thay Seow Gary Suttle Wallerstein Foundation for Geriatric If your name is Loyal Order of the Moose Amy Miller Gail and Patrick Oliver Carolyn and Michael Richards Mr. and Mrs. Jeffrey R. Sharp Michael Sweeney Life Improvement misspelled or Lynn and Daniel Lucier Sandra Miller Patrick D. Olsen Verna Richardson Sharp Communications, Inc. Nancy and Bruce Swenson Edward Waltemath missing from Megan Lucier Millie Viqueira and Steve Miller Oliver Wyman, Inc. Norman & Myrna Ricken Sheryl and William Sharpe Heather and Hayden Swofford Warner Truck Center this report, Michelle Luethy John Metzger Shelley Olson and Ramiro Moreno Charitable Trust Harlene Shaw Natalie and Ben Taber Barbara and Marc Warren Lynn H. Lullo Janice Miller Madeleine D. O’Mara Nancy and Richard Riordan Patti and Martin Shenkman Mr. and Mrs. Harold M. Tague Anne and William Washychyn please accept Diana Lum Joanne McElligott and Douglas Millett Tim O’Neil Barbara and Craig Robbins Esther Shen-Wilson Kelly and Andrew Tait Gayle and Michael Wasserman our apology Gail C Lussier Cheryl and Philip Milstein Toni and Eric Oosting The Robbins Family Foundation, Inc. Marjorie Shepard Sabrina Tamraz Lori and Denton Watumull and email Karri L. Lyman Minikes Charitable Foundation Marilyn and Ben Ossman John Roberts Eleanor and Roger Shepard Edward Taran David Weber the correct Michael & Louise Lynch Charitable Susan and Harvey Mininberg Robert Ousterhout The Michael Graeme Robertson Aidan, Alexis, William and Maeve TEM-PACE, Inc. Steven R. Wechsler information to Foundation, Incorporated Ruth and Robert Mirvis P & F Industries, Inc. Foundation Shepardson Tempe Precision Ltd. Eliot and Beth Wegbreit Lyondell Chemical Company Missionfish-Polf Ann Marie and Timothy R. Painter Frank & Lorraine Rodgers Family Marilyn and Rex Sheppard Cindy and Robert Theberge Julie and Peter Weil donations@ The Jack & Marilyn MacAllister Shelly and Frederick Molineux Chester Panek Foundation Michael Sherman Lisa and Martin Thenell Harry D. Weininger michaeljfox.org. Foundation Monaco Mechanical, Incorporated David Panzirer Debbie and Rob Rodin Karen and Ben Sherwood Susan Thiel Christine Kelly and MacKenzie Community Monterey Peninsula Foundation Paramount Capital Group Andrew Roffe Chris Shummay Mary and Homer Thomas Morton O. Weinress Madison Avenue Pharmacy Monterey Peninsula Host Lions Club Parkinson Education Program of Roll Giving Anthony Sichenzio Frank and Margaret Throssell Fund Andi and Bob Weiss Elizabeth A. Malone M. Slavin & Sons, Ltd. Delaware Marilyn Roseberry Margot Siegrist Matthew Tittler Ellie and Norman Weiss Sara Jane Manning M. W. Montgomery Adam Parrish Mr. and Mrs. Steven Rosen Ben Sihota Gail Tomberg The Adam J. Weissman Foundation ManTech International Corporation Richard D. Montross Florence H. Pattee William Rosenbaum Robert Sill Paula Tomlin Julia and David Weisz Patricia Marinilli Barbara Moore Frances Paulsen Ora Rosenberg Kathy and Marc Silverstein Berte L. Toppell Welby Kitty, Inc. Joe Marinucci George Moore Brook and Amy Payner Lauren and Michael Rosenthal Amy and Steven Silverstein Alice and Joseph Torre Jane Wenner Janet Marks Breedlove Rob Moore John P. Peavy Tibby and Abby Ross Joann and Joel Simkins Allison Townsend Reese West MJFF ANNUAL REPORT 32 2008 DONOR LISTING 2008 DONOR LISTING 33 MJFF ANNUAL REPORT

Lisette L. Ackerberg Louise A. Canterbury Michael J. Fox James L. Hoey Edwin A. Levy Lucy B. Nesmith Edward V. Rittenhouse Lynda Spann Christine M. Adlong Ross M. Canty Schuyler Fox Everett K. Hoffman Richard L. Levy Kim T. Nguyen Robert J. Reby & Company Clients Anne-Cecilie Speyer KC Agrelius Anita Canzano Darryl Frank James R. Holmes Bertha Lipshutz Jodi Niblack Kathleen E. Roberts Jack Spillman Alex Aidekman Colleen Carey Libby Fraser Loretta Holtzman John I. Lough Carl B. Nieslanik Michael G. Robertson Terry Splain Abdullah S. AlFuhaid Edward G. Carpenter Dennis Freund Nathan Holtzman Rhoda Lowenstein John J. Nitti Sonya Rodin Dolores Stallman Patricia M. Altman DeWayne Casey Helen Fronstin Katie H. Hood Rita V. Lulla Mother of Virginia W. Norris Robert T. Rolfs Carole J. Starr George R. Anderson James E. Cayne Walter Fronstin Richard E. Hoover Julian Lurie William J. O’Connor Michael M. Roseberry Susan A. Stephens Sarah M. Apfel James Cesa Barbara S. Frumkin William M. Houston George J. Lussier Mark A. O’Donnell Sheldon Rosenfeld Lewis R. Stevens Carolyn Arden Elizabeth A. Chase Gerald Furr Karen K. Hovey Marian L. Madendieck Swen Olaussen Phyllis Rosenfield Donald J. Stewart Donations Janet Arter Gloria Cherry Karl A. Gabler Anne A. Hubbard Anthony Malo Kenneth L. Oliver Robert Rosenfield Stanko S. Stojkovic have Linda J. Ashe Abhijit D. Chodry Esther Galing Thomas W. Huffstutler Bob Mann Ronald W. and Isabelle T. Olsen Richard M. Rothenberg Edward A. Strebel generously Katherine G. Bahas Sonya Chodry Robert R. Gallagher Jack W. Hugus Michael J. Manning William Ousterhout Lucile B. Rowe Kelly Stuart-Montemayor been made Benjamin H. Balkind Sandra Christensen Abbie Gardiner Edward P. Huisking William Y. Mark Donald G. Paige Josef Ruepp Gary Suttle Jerome E. Ball Liz Christopher Gary Garofano John R. Humphrey Ian Markofsky Ariana Palacio Deannie Rule Tara Swaminapha in tribute Shirley Bandy John Clark Patricia Gateff Alan G. Hurwitz Ellis L. Marks Victor L. Palumbo Stanley Sabatka Laura Swan to the following Bettye Baria Dennis R. Cobb Melvin Gerber Noel S. Hysell Virgil Marrocchino Joseph Parato Jean H. Sager Robert Sykes individuals and Melville R. Barlow John W. Cogger Jack Giesecke Brian H. Jackson Harry Marshall Julia Park Constance Saltarelli Stanley Tallon organizations. Joseph W. Barnett Barry J. Cohen Kenneth H. Gilbert Seymour G. Jacoby Aaron Martinez Thomas D. Parnell Mary Sandell Jerome Tamkin Michel Barret Richard Cohen Ronald I. Gilje Meera Jain Vincent F. Marzulli Don Parrish Edith Saunders The Dicus Family Henry B. Basch Thomas P. Collins Donna B. Gillespie Irene Jedinak Marie J. Massaro Marvin E. Parry Vik Sawhney The Pig Classic Gerald Basie Louis P. Collito Cathy Gin Shirley Jenkins Albin J. Mauer Joseph C. Pattee Giuseppe Scattone Joseph A. Thomas Derek Bauman Jim Connor Donna J. Gioiele Charles Johnson Michael R. McConnell Alfred J. Paul James F. Schell Teresa Thomas John Bauman Arthur Coombs Marguerite Giomini Frank L. Johnson Marion J. McCormack Eric Paulsen Herbert M. Schene Lois M. Thornbrugh Charles Beattie Louise Cotugno Albert B. Glickman James R. Johnson John M. McFarland Marlys Pearce Ally Schenker Jack Toppell Luella Becker Bruce Crawford Jeffrey L. Glickman Marian A. Johnson John V. McMillan David H. Peery Curtis Schenker Rita E. Trembler Michael Bedigian Don Crisup Nondis Gochoel Freeman P. Jordan John McWilliams Amanda Peet Jack Schiffman Wallace Tripp Shirley R. Belch James O. Currie Stanley G. Gohlinghorst Sharon Juroff Kenneth A. Meister Isabel Perez Alanna Schroeder Miller H. Ullmann Jack Benaroya Virginia J. Da Rin Dusan M. Gojkovich Julie Kalish Harry Melnick Raul Perez Anita Schroeder Frank A. Uribie Raymond Benner Douglas C. Dahn Les Golding Mary Kamal Charles Melton Ruth I. Perlman Jo Ann Schwartz Nelson Van Judah Jerome Berman Olleen S. Davis William L. Golding Janet Kaplan Scott Meril Peggy A. Peters James A. Scott Marlene VanLoh Howard Bidwell David A. Deering Neil Goldman Mickey Kaplan Joel Metzger Michael Peterson Jana E. Seagreaves Jack A. Vennes Evan Binder Susan E. DeFina Mark Golebiowski Raymond Kaplan Richard M. Meyer Joseph H. Petrozzini Patti L. Semanek Edward C. Venti John Binder Tina Deggs Margot Gosen Robert A. Kaplan Mary-Lynn Mika Ilya Piatetski-Shapiro George Sgouritsas George M. Walish Irving M. Biskin Karen DeRe Jill M. Graham Stephen B. Keyser Julie Milam Lillian M. Picciuto Paul R. Shalita George Walters Carl J. Block John A. DeSano Gavin O. Gray Dianna Kidd Ellen Miller Raymond E. Pittman Herbert E. Shaw David E. Warrick Catherine Bohjalian Florence C. DeSilva Elliott S. Greenspan Edna King Leo Miller Albert B. Polen Edward M. Shea Alice Weiss Allen A. Bohner Michael E. DiGiulio Matthew Greenstein John W. King Margaret K. Miller James D. Polis Margaret Sheehan Stephen Welty Michael C. Borre Sherie Dolinoy Curtis Greenway Viola King Walter Minkoff Tracy Pollan Therese Sheehan Gloria S. White Rose Borton Garrett Donovan Grace S. Griffith Rollin Kingsley Patricia L. Moberger Laurente Pomponi Norman E. Shepard Bill J. Whitworth Emma Bouzek Rick Doppler Amy Gross Mary D. Kipps Joan Monaghan John B. Pope Stuart S. Shepard Rose A. Will Murray Bowes Theodora Dys William A. Gruy James Kirk William D. Montgomery Cindy Porter Brian H. Shoemaker Linda P. Williams Susan S. Bracken Roy A. Echeverria Arron Gurney Holly Kitay Samuel J. Morano Joel Portnoy Helen Shular William C. Williams Jeffrey M. Brandsma Rose Edwards Donna Hanna Andrew J. Knobbe Brian Morrow George E. Prescott Norman L. Shulman Robert L. Willis Susan B. Bressman David Einhorn Harold F. Hardman George T. Kobori Morgan Most Robert Pritzker Daniel Shuman Harold G. Wilson Sergey Brin Wallace C. Eisele Richard Harmon Eugenia Koog Howard W. Muffler Michael J. Quinn Andrew Siegel Elsie Winn Lisa Brodsky R. Park Ellis Carey Harton Vasilios Kotsias Richard V. Mulcahy Lynne D. Raider Sheldon Silverstein Jean Wixson Martin J. Bromley Thomas English Arthur D. Hearne Barbara Kraly Dan Murphy Gopalan Ramadorai John R. Singer Maxwell Wolff Betty Brown Veronique Enos Marcia Hearne David Krowe Richard C. Murphy Robert Ramirez Frederick J. Sisson George H. Wong Robert Brown Alfred J. Evans Josephine Hecker John N. Lam George M. Murray Gary L. Randall Leo J. Sklar Raymond P. Wong Sylvia J. Brown David Fagell Robert A. Heise Steve Lane Kathleen M. Mutter Theodore M. Ratica Arline Slepoy Florence L. Woolery Edward J. Brownstein Audrey H. Feravolo Max P. Heller Robert E. Larson Lee D. Mutter George H. Rau Howard Sloan Jennifer B. Wroan Robert D. Bruce Louise Ferguson John I. Hellin Ira Lash Eva Myers Joseph H. Reich Arthur Sloane Charles Yassak Robert Buchanan Karen L. Finerman Laura Henriksen Wallace Laudeman Irwin Nadel Florence Reid Beatrice Smith Thomas J. Young Florence S. Bunn William E. Finnigan Chriscinda Henry Garth Leas Annie M. Nahigian Barbara A. Reinke Bradford H. Smith Paul N. Zimmet William O. Burnett Bruce Fischer Mark Heppenstall Harry Lenger Jack Nash Richard Reiss Patrick Smith Marta Zivarts Gerald G. Burns Harold J. Fitzgeorge Robert Heppolette Mario W. Leombruni Robert G. Nash Valerie L. Remnet Martha Snow Henrietta Zlotnick Gerald F. Burns Thomas Fitzpatrick Frederic L. Herzfeld William B. Leonard Jack A. Naviaux Ernest F. Rice Raymond N. Sordoni Judith Zola Barbara C. Calvert Terence J. Fortune Blain D. Hightower Murray Levitt Maurice R. Nazareth Deborah Ridel Anthony J. Sorosky Iva V. Zucca Janet E. Campbell Aquinnah Fox Ethel D. Hill Arnold Levy Francine Nejame Marilyn Rinsler Gus E. Sotir MJFF ANNUAL REPORT 34 2008 DONOR LISTING 2008 DONOR LISTING 35 MJFF ANNUAL REPORT

is thousands of amazing people all over the world who are walking, Dori Miller Amy Miller Tamra Cantore Mark Gherty Madison Lyleroehr Amanda Reed running, blogging, jogging, paddling, pedaling, eating, drinking, shopping and dancing to raise English Channel Swim Twin Cities Marathon Team Cantore Fundraisers American Birkebeiner Heavenly PeaceMadison 2007 ING NYC Marathon Kevin Murphy Mary Ann Neilson Lisa Clark Hunter Hall Anne Maglia Susie Rosenthal funds and awareness for MJFF and Parkinson’s research. San Francisco Marathon Keystone State Corvette Club Poker 2009 Boston Marathon Chicago Marathon Show-Me State Games Team Fox Fundraiser Gail Oliver Run for Parkinson’s Disease Vicky Clark Jon Halle Andrew Maguire Martha Ruest In Team Fox’s first three years, members raised an astounding $5 million and this diverse Mrs. Mo Memorial Golf Tournament Shelley Olson Team Fox Fundraiser Car Wash Big Lake Half Marathon 2007 ING NYC Marathon community of changemakers continues to grow and inspire us every day. There is no limit to James Ostryniec Olson Family Father’s Day Fundraiser Cherie Crowningshield Hal Halvorsen Barbra Sue Miller Jill Sabatine the creativity and optimism of Team Fox members who have made it their personal mission to Birthday Party for Parkinson’s Alpha Tau Omega Paddle for a Cure Boston Marathon Long Beach Marathon Berlin Marathon make Parkinson’s disease nobody’s disease. Joseph Palicki 2nd Annual Charity Chili Cook-Off Jen and Bob Davis Oliver Holler Greg Myers Thomas Sabourin Roses Amongst the Thorns Benefit Jane Park Dallas White Rock Marathon ToTheFuture.org Chickamauga Battlefield Marathon Team Fox Runner Concert LPGA U.S. Women’s Tour Taylor Dewey Janie Hoover Leah Nitishin Roy Schifilliti Colette Porcelli Laura Philo-Diaz Pedal and Paddle for Parkinson’s Team Fox Fundraiser PF Chang Rock and Roll Half Cape Cod Marathon $50,000 or more Gary Cervantes Steven Chrzanowski Inn at Quogue Fashion Show Castlerock Open The Dorsey Family Eugenia Kaye Marathon Shawna Schueller David Eger Annual BBQ Team Fox Fundraiser Gary Rubin Allison Platt Gumball Guessing Challenge PDHope Brendan O’Connell Twin Cities Walk for Music for Parkinson’s Research Greg Drumheller Katie Clark Boston Marathon Party for Parkinson’s Tim Egan Carol Kennelly Team Fox Fundraiser Parkinson’s Disease Wilkins Media Company Texas Hold’em Poker Tournament Chicago Marathon Kyle Turner Jim Racine Chicago Irish Brotherhood Cooking for a Cure Mitsuko Ogawa Joan Shepp Polo for Parkinson’s Tracey Earl Dance for a Cure 24 Hours of Moab Mountain Boston Marathon Event Peter and Brooke Kotsonis Chicago Half Marathon 60s and 70s Fashion Show Buckles and Spurs Gala Ciao Parkinson’s Bike Race David Sack John Fitzmaurice Disney Marathon Michala Kinney The Regulars $25,000 or more Nicholas J. Frasso The Deery Family Colleen Wuebben Boston Marathon Marine Corps Marathon Jeffrey LaGrange Pubbin’ 4 Parkinson’s 10 Mountains - 10 Years Marian C. Bell Foundation Help Hook The Cure Striped Bass Dick Deery Run/Walk for MSA Team Fox Skate-a-thon Kevin & Colleen Schirf Sarah Gerk Team Fox Fundraisers Cyrus Rajabi (A Quest for the Cure) P.A.R for Parkinson’s Golf Event Derby Sydney Epstein Kathy Zweifel Amica Insurance Breakers Marathon Marathon Runner Peter Liberto Birthday Party Benjamin Terry Susan Bilotta Ken & Ann Glowienke Pancakes for Parkinson’s Party for Parkinson’s Skykings for Leonard Cyphers Lev Gershman Dover’s PD Support Larissa Raze Monument Ave 10K Tips for Parkinson’s Focus on a Cure Picnic in the Elan Ezickson 39th Annual Peachtree Team Fox Fundraiser Group Fundraiser Team Fox Fundraiser Michael Costa PARKinson’s London Marathon $2,500 or more Road Race - 10K The War on Parkinson’s Karen Harrison Vince Ferraro Laurie Allen Rik Spier Softball Game Boston Marathon Mashie Niblick Golf Classic Reach Out Hearts Mini Marathon 5K Walk/Run The Greif Family Karen Janos The Friel Family Donna Carnevale Matt, Angie and Kristin Sremba ING NYC MARATHON In 2008 Team Fox was proud to be selected once again as an Sara Runnels Friends of Parkinson’s Twilight Movie Screening Cure PD 5K Race / Walk & Boston Marathon 1/2 Ironman, Marathon and 25K official charity partner in the ING New York City Marathon. 130 runners from four countries Jeremy Ryerson Golf Outing/Texas BBQ Junior Hollywood Radio and Kids Fun Loop Janet Clough The Tjader Family Emily Sarokhan Ohio State University Television Society Scott Giffney Team Fox Five Mile Walk Tjader Family Fundraiser and 20 U.S. states teamed up to raise $570,000 and bring us all 26.2 miles closer to a cure. Adam Shepherd Pancakes for Parkinson’s JHRTS Holiday Party Party for Parkinson’s Whitney and Aaron Cooley Lisa Unger Lara Spagnuolo $100,000 or more Peggy Pichi Matthew Goldstein Mary Anne Ostrenga Natalie Karp Ryan Grant Whitney VanderWeerd/Aaron Cooley Jarden Westchester Triathlon Marie Spodek Ryan Reynolds Winthrop Smith Katie Griffith Garden Walk & Sunset Reception Canyon Ranch Group Trips Team Fox Fundraiser Wedding Favors Nanette VanAlstyne Robert Stanlake Team Fox Celebrity Chair Tammy Hoblak Josephine Poehlmann Beth Murray Gene Gurkoff Lewis & Daggett Mailing Event $2,500 or more Simon Stanlake Danielle Jacobs-Erwin Stewart Wallace $25,000 or more Katie Barker Elizabeth Stevens 6th Annual Benefit in Memory of Tom Parade for Parkinson’s Home Tour Kona Ironman A Touch of Class Richard Jones Alyssa Johnson and Loren Berger Jacquelyn Strycker Poehlmann Pinky’s Passion for a Deborah Hagel Eagle Bridge Foundation Students Give Back Kari Keane Barry Cohen Jeroen Cammeraat Sabrina Tamraz Rucker’s Candy Parkinson’s Cure Team Fox Dinner Party EBF Golf Weekend Morag Webster Sheila Kelly Andrew Fitzgerald and Ron Carlson Susie Teal LCPDA Golf Classic Fundraiser Pinky’s Passion for the Fabulous Daniel Harding Hazel Elsbach London Marathon Ann-Marie LaPorta Richard Fitzgerald Galia Clemens Tricia Tinney Evan Schumacher Fifties Colorado Young-onset Parkinson’s Read-a-thon Eileen Werndorfer Angela Leontaritis Thomas Clifford Lindsay Totams Boston Marathon Jacqueline Talarico Disease 5K Run/3K Walk Tim Flannigan Brookfield Parkinson’s Walk/Run $10,000 or more Anne Lewis Tim Crowley Danielle Vasak Megan Shackleton Jacqueline Talarico Designs Harvard University Mark’s 40th Birthday Luau Kat Milly West Sheila Brand Marc Lindenman Patrick Culligan Ed Werner London Marathon Jewelry Sales Pancakes for Parkinson’s Ruth Greensides Friends of Kat 5K Edward Casey Marc Todd Lowe Adam Cummings University of Virginia Brian Thorne Elisa Holscher John D. Hawkes Memorial Walk Diana Wiesner Veronique Enos Adam Maiocco $1,000 or more Nicholle Davis Pancakes for Parkinson’s Cruising for a Cause Ironman Arizona Caitlin Harrington Disneyland 1/2 Marathon John Houston Joe Marinucci Amy Albright Dayna De Simone Elizabeth Woodbury Warsaw Center Diane Kinsey 81 Miles for a Cure Ken Kubota Ann Markley Jason Bennett Timothy Diamond 4th Annual Spring & Summer Jog for Jim 5K Walk with Mary Alisa Hoadley $1,000 or more Amy Lee Shawn Martin Jenny-Brooke Condon Bob DiSabato Style Show Sara Adland Kenneth Olson Steve Martinetto Anthanette Fields The Wistran Family Eugenia Koog 5K Race for Parkinson’s Christina DiSabato Michael Maslar Bradford Kear The Woods Family North Shore Walk for Parkinson’s Play for Parkinson’s Christine Hoffmann Baltimore Running Festival - CareFirst James Driscoll $5,000 or more Maggie Mathews Mary Kelly The New England Parkinson’s Ride Neil Korf London Marathon BlueCross BlueShield Half-Marathon Jacob Elberg Maureen Ashdown Matthew Milton Shawn Kingsley $5,000 or more Team Fox Fundraiser Andy Laegeler Jonathan Artz Jessica Ernst Beth Baker Catherine Moe Michele Kustera $10,000 or more Sam Ayling Joanna Laubscher Ironman Arizona Boston Marathon Dan Fagin Seanna Bruno Richard Mueller Frank and Diane LaDore Arrowhead Inn London Marathon Whirlpool Steelhead 7 David MacBean James Beattie Michael Fagin Lisa DeLusignan Julie O’Hagan Kevin Levine Arrowhead Open Golf Classic Curtis Bouman 0.3 Triathlon Boston Marathon Team Fox Fundraiser Jamie Forman Dan Dreiling/Pocket Change John Patton Liesl Lilly The Bechtel Family Team Fox Fundraiser Gary D. Leith Foundation for Kassie Marino Jan Bogner Mark Frasier 4 Parkinson’s Torin Peterson Erin Loebner Bechtel Family Fundraiser Paul Brundage Parkinson’s Research, Inc. Birthday Party in Honor of Uncle Lou Put the Fire Out for Parkinsons Marisa Friedman Jeremiah Driansky Allison Petty Michael Ryan Peter Bleiberg Dennie Bridges Kate Gannon Team Fox Fundraiser Finding a Cure, Together Dustin Matthews Jordan Goldwarg Anthony Piracini Richard Salerno Ashley Gilbertson Boston Marathon Stephen Callahan Golf Classic Hacker’s Cup Golf Tournament Book Sales Alexis Howard Nancy Prior Melissa Shaw Lori Gillen Carsten Boesmann Five Hole Open Al and Beth Levine TigerBill Meligari Beth Buzza Anita Johnson Jen Reed Andrew Vale Jim Goldenziel Ride Against Parkinson’s Pedaling for Parkinson’s TigerBill’s Drumbeat Festival Scott Tinley’s Adventures Terry McCarty Lauren Rich Lee Vartan Howard Goldstein Road Triathlon Andrew McLean Susan Rubino David Weber

MJFF ANNUAL REPORT 36 2008 DONOR LISTING 2008 DONOR LISTING 37 MJFF ANNUAL REPORT

Abbott Laboratories, Employee Employees Charity Organization John Hancock Financial Services, Inc. Sanofi Aventis Matching Giving Campaign The Duke Energy Foundation Johnson & Johnson Family of Gifts Program FINANCIAL HIGHLIGHTS Adobe Systems, Incorporated Energizer Matching Gift Program Companies Matching Gift Program SAP Matching Gift Program Matching Gift Program Fannie Mae Foundation JP Morgan Chase Foundation Select Equity Group Foundation Aetna Foundation, Inc., Partners in First Data Foundation Matching Gift Program Sony Corporation of America Community Giving The Ford Foundation Matching Gift KPMG The Sun Microsystems Foundation AK Steel Foundation Program Kraft Employee Involvement Programs Teledyne Technologies, Inc. Allstate Insurance Giving Campaign Fortress Investment Group LLC KTLA-TV Matching Gift Program Altria Employee Involvement Programs The Freddie Mac Foundation Lehman Brothers The Amgen Foundation Efficiency. Accountability. Impact. We are grateful American Express Foundation Matching Gift Program Lyondell Chemical Company Thrivent Financial for Lutherans to these Company Employee Giving Gannett Foundation McDonald’s Corporation Foundation We demand the same accountability and transparency companies for Campaign Gartner Matching Gift Center The McGraw-Hill Companies Employee Tyco Employee Matching of ourselves as of our awardees, and we keep a tight rein their generosity American International Group, Inc. Bill & Melinda Gates Foundation Giving Campaign Gift Program on expenses. Fiscal accountability and transparency are Applied Materials GE Foundation Medco Employee Giving Campaign Unilever United States core elements of our organizational values, particularly in in matching Automatic Data Processing, Inc. Genentech, Inc. Merck Partnership for Giving Foundation, Inc. employee gifts Bank of America Charitable Give With Liberty Merrill Lynch & Co. Foundation, Inc. United Way of the how we spend supporters’ contributions. While we believe to MJFF. Foundation GlaxoSmithKline Matching Gift Program Capital Area, Inc. that a quality enterprise requires investment, we are proud Bank of America United Way Global Impact Microsoft Corporation Matching Gift United Way of Tri-State that, since inception, 85 percent of our funds have gone Campaign Goldman, Sachs & Co. Matching Program Verizon Foundation The Brown Foundation Gift Program Motorola Foundation Wachovia Foundation Matching directly to research program efforts. The Capital Group Companies Goodrich Corporation NIKE Employee Matching Gift Gifts Program We deliberately have no endowment, instead seeking to Charitable Foundation Google Oracle Corporation Washington Mutual Employee CDW Corporation Grainger Matching Charitable Pfizer United Way Campaign Giving Program deploy funds raised as quickly and wisely as possible. Chubb & Son Gifts Program The Phoenix Foundation, Inc. Wellpoint/Unicare Associate This is an unusual strategic position for a nonprofit. But we Citigroup Matching Gift/Volunteer Hewlett-Packard Company Piper Jaffray Matching Gift Program Giving Campaign believe that to find a cure for PD as quickly as possible, our Incentive Programs HSBC Community and Philanthropic Portland General Electric Company Wells Fargo Community Support capital needs to push research forward today — not sit in Davis Selected Advisers, L.P. Service The Prudential Foundation Matching Campaign Deutsche Bank Americas Foundation Illinois Tool Works Foundation Gift Program The Williams Companies an endowment or reserve. In 2008 this philosophy proved Matching Gift Program Indianapolis Power & Light Company Qualcomm Matching Grant Program Foundation, Inc. especially prescient. With no investment portfolio, MJFF Deutsche Bank Securities, Inc. Jefferies & Company, Inc. The Robert Wood Johnson Foundation XL Reinsurance America, Inc. suffered no investment losses. Dominion Foundation Rummer Medical Distributing, Inc. We are outcomes-focused, incorporating milestones and tying grant payments to achievement of those milestones. We fund promising, high-potential research 2008 COMMUNITY FUNDRAISERS The Foundation is grateful to the following donors projects as long as they remain on track. We work with for their generous efforts to raise funds and awareness for MJFF and Parkinson’s research awardees to troubleshoot and tackle problems as they through community fundraising events. arise, but if the science stalls, we halt funding so that limited resources can be reallocated to other efforts.

$50,000 or more $2,500 or more Episcopal Church Women of We proactively measure the impact of our dollars Anne-Cecilie and Rob Speyer Federal Aviation Administration Christ Church, Frederica GVI Property Management Spencer Fried on the pace of Parkinson’s research progress. Our $25,000 or more Bruce Levitt Lydia Hires in-house research team scores the outcomes of every Vintage Rallies, Inc. Sundance Running Club I Do Foundation grant we make, in the interest of assessing impact and Andrea Konsky maximizing learning to inform future efforts. In 2008 we $10,000 or more $1,000 or more Lincoln Elementary School Apple Optical Anchorage Parkinson’s Disease MissionFish also conducted an external audit of our research program, Michael Cotoia Support Group Kerry M. Mitchell/NorthWest asking unbiased advisors to help evaluate our efforts. Firstgiving, Inc. Adriana Avitia Indiana PD Support Group ITSource Technology Michael Brodnax Monterey Peninsula Foundation We measure our impact not by input — dollars raised Rosemary Beach Foundation, Inc. Cambridge Area Parkinson Mark O’Donnell — but by output — scientific advances achieved. We’re Support Organization Stuart Rothstein proud of what we’ve accomplished to date. But ultimately $5,000 or more Amanda Coombs Ralph Silwa Samantha Kitchen John Copeland Lindsay Spring we have only one definition of success: Scientific solutions Parkinson’s Support Group of Pamela Cundall Wachovia that produce tangible improvements in patients’ lives. Rochester NY Inc. Entertainment Industry Scars Into Stars Charity Foundation 2008 financial highlights follow. Full audited financials and our most recent IRS Form 990s are available at www. michaeljfox.org. MJFF ANNUAL REPORT 38 FINANCIAL STATEMENTS FINANCIAL STATEMENTS 39 MJFF ANNUAL REPORT

The Michael J. Fox Foundation for Parkinson’s Research The Michael J. Fox Foundation for Parkinson’s Research STATEMENT OF FINANCIAL POSITION STATEMENT OF ACTIVITIES

Year Ended December 31, 2008 2007 Year Ended December 31, 2008 2007 ASSETS Public support and revenue: Cash, cash equivalents and investments $ 30,962,536 $ 32,185,002 Contributions $ 35,335,877 $ 30,613,241 Contributions receivable, net 26,762,424 15,566,497 Special events 6,741,990 7,087,215 Prepaid expenses and other current assets 162,958 37,015 Investment income 662,655 748,194 Security deposits 33,061 33,061 Miscellaneous income 25,682 117 Property and equipment, net 388,610 518,718 Total public support and revenue 42,766,204 38,448,767 Total assets $ 58,309,589 $ 48,340,293 Expenses: LIABILITIES AND NET ASSETS Program services 36,236,785 26,270,247 Liabilities: Management and general 1,093,996 1,017,356 Accounts payable and accrued expenses $ 1,066,594 $ 957,787 Fund-raising 4,130,806 3,947,418 Grants payable, net 38,882,706 31,331,041 Total expenses 41,461,587 31,235,021 Deferred rent 367,192 376,270 Loan payable 1,013,285 — Change in net assets 1,304,617 7,213,746 Total liabilities $ 41,329,777 $ 32,665,098 Net assets, beginning of year 15,675,195 8,461,449 Net assets, end of year $ 16,979,812 $ 15,675,195 Net Assets: Unrestricted (deficit) (5,516,236) 6,766,811 Temporarily restricted 22,496,048 8,908,384 Total net assets: 16,979,812 15,675,195 Total liabilities and net assets $ 58,309,589 $ 48,340,293

Note: Investments are in highly liquid U.S. government securities.

RESEARCH PRIORITIZATION 2008 OUR OBSESSION WITH EFFICIENCY 2000-2008 GROWING INVESTMENTS IN PD RESEARCH 2001-2008

35 $ 33 Translational Research 66% Research Program Activities 85% 30

25 $ 24 $ 24 Transforming Discoveries into Targets 20 Administration 3% $ 17 New Tools and Technologies $ 15 15 $ 14 $ 12 10 Fundraising 12% 5 $ 4 Clinical Research 27% Understanding Disease 7% 0 2001 2002 2003 2004 2005 2006 2007 2008

Dollar amounts in millions. Does not include 2001 R21 awards in partnership with NIH.

MJFF ANNUAL REPORT 40

Photo and Illustration Credits Progress: The 2008 Annual BOARD OF DIRECTORS SCIENTIFIC ADVISORY BOARD Progress: The 2008 Annual Report of Report of The Michael J. Fox Foundation The Michael J. Fox Foundation for Parkinson’s Research On the Cover Pages 12–13 for Parkinson’s Research was published George E. Prescott Gene Johnson, PhD* was published in June 2009. It is available in PDF format Midbrain cells expressing potentially Nanoparticles of condensed DNA image in June 2009. It is available in PDF Chairman Chief Scientific Advisor therapeuticat dominant/negativewww.michaeljfox.org. TNF. Image courtesy of Copernicus Therapeutics, Inc. format at www.michaeljfox.org. courtesy of Malú Tansey, PhD, University of David Golub Katie Hood Structure of alpha-synuclein courtesy Katie Hood Irene Hegeman Richard, MD* Texas Southwest Medical Center at Dallas. CEO of Mark R. Cookson, PhD. Redrawn from CEO Vice Chairman Senior Medical Advisor Dr. Tansey is funded by The Michael J. Fox publicly available data (protein databank ID Foundation to study the role of TNF and Michael J. Fox 1XQ8), derived from experiments described Michael J. Fox Holly S. Andersen, MD inflammation in the death of dopamine Alberto Ascherio, MD, PhD Founder by Ulmer et al. in J Biol Chem. 2005 Mar Founder Eva Andersson-Dubin, MD neurons in Parkinson’s disease. To learn 11:280(10):9595-603. Erwan Bezard, PhD more about her work, see page 6. Deborah W. Brooks Jon Brooks Anders Björklund, MD, PhD Deborah W. Brooks Schematic of RNAi therapeutic process by Co-Founder Barry J. Cohen Page 3 Co-Founder Jennifer Fairman/Fairman Studios courtesy Susan Bressman, MD* Photo of Katie Hood by Elena Olivo. of Alnylam Pharmaceuticals, Inc. Donny Deutsch Robert E. Burke, MD Photos of SMichaelandy D J.rayton Fox and Debi Brooks David Einhorn Page 15 Marie-Françoise Chesselet, MD, PhD by Mark SViceeliger President, courtesy of SCommunicationseliger Studio. Sandy Drayton Karen Finerman iPS cell image courtesy of Patrick Lewis. Vice President, Communications P. Jeffrey Conn, PhD* Nelle Fortenberry Page 5 Writer/Editor: Holly Barkhymer Structure of the largest fragment of a Mark Cookson, PhD* Photo of AAssociatenders Björklund Director, and Manolo Communications Carta LRRK2-related protein available to date Writer/Editor: Holly Barkhymer Michael J. Fox David Eidelberg, MD courtesy of Manolo Carta. courtesy of Mark Cookson. Redrawn from Associate Director, Communications Albert B. Glickman Contributor: Dana Ipri Matthew Farrer, PhD Schematic courtesy of Anders Björklund. protein databank deposition 3DPU. Communications Officer/Team Fox Officer Contributor: Dana Ipri Skip Irving Chip Gerfen, PhD Communications Officer/Team Fox Officer Pages 6-7 Page 20 Kathleen Kennedy J. Timothy Greenamyre, MD, PhD Designer: Susan Shaw Cells expressing TNF image courtesy of Top row, clockwise from left: Designer: Susan Shaw Morton M. Kondracke Etienne C. Hirsch, PhD Susan Shaw Design Elena Olivo Malú Tansey. Susan Shaw Design Edwin A. Levy The Michael J. Fox Foundation Oleh Hornykiewicz, MD Photo of Malú Tansey courtesy of UT Courtesy of Veronique Koch Kenneth Olden, PhD, ScD, LHD Southwestern Medical Center at Dallas. Ole Isacson, MD (Dr Med Sci) Courtesy of Anthanette Fields Douglas I. Ostrover Joseph Jankovic, MD Photo of Jeff Conn courtesy of Vanderbilt Middle row, both photos: The Michael J. Fox Foundation gratefully Tracy Pollan Medical Center. acknowledges Bulkley Dunton for donating the Jennifer Johnston, PhD The Michael J. Fox Foundation gratefullyW acknowledgesireImage/Dimitrios Bulkley Kambouris Frederick E. Rowe (Shad) Photo of Stephen Traynelis courtesy of Emory high-quality McCoy Silk Cover and Text paper Jeffrey H. Kordower, PhD Dunton for donating the high-quality McCoyBottom Silk row: Cover and Text University/Jack Kearse. on which this annual report was printed, and Lily Safra J. William Langston, MD paper on which this annual report was printed,Courtesy and of The Rachael Ray Show/ EarthColor, Inc., for printing this report Curtis Schenker Olle Lindvall, MD, PhD* Electron micrograph image of glutamate David M. Russell below cost. receptor immunoreactivityEarthColor, Inc., (unpublishedfor printing this report below cost. Woody Shackleton Andres Lozano, MD, PhD Page 21 data, Y. Smith) courtesy of Stephen Traynelis. Our gratitude to Hearst Corporation for Daniel E. Spitzer, MD Kenneth Marek, MD Our gratitude to Hearst Corporation for Topfacilitating row: both facilitating both donations. Fred G. Weiss Pages 8–9donations. Isabel Wilkinson Eldad Melamed, MD Photo of Lisa Shulman courtesy of University Middle row, clockwise from left: Kalpana Merchant, PhD* of Maryland. Ann Billingsley The Michael J. Fox Foundation is a 501(c)3 C. Warren Olanow, MD Schematic showing effects of isradipine, WireImage/Jamie McCarthy FOUNDERS’ COUNCIL nonprofit organization. Theo Palmer, PhD Chan et al., courtesy of D. James Surmeier. Ann Billingsley Ira Shoulson, MD © 2009 The Michael J. Fox Foundation Lonnie and Muhammad Ali Pages 10–11The M ichael J. Fox Foundation is a 501(c)3Bottom nonprofit row, left–right: for Parkinson’s Research Steven A. Cohen Andrew Singleton, PhD File photoorganization. of Iwona Strycharska-Orzyk Ann Billingsley David G. Standaert, MD, PhD provided by The Parkinson’s Institute and The Michael J. Fox Foundation John A. Griffin Clinical C©enter. 2009 The Michael J. Fox Foundation forElena Parkinson’s Olivo Research Andrew S. Grove Dennis A. Steindler, PhD Photo of Michael Schwarzschild courtesy Page 22 Jeffrey Katzenberg Caroline Tanner, MD, PhD of Massachusetts General Hospital. File photo provided by The Parkinson’s Nora McAniff David Weiner, MD* Institute and Clinical Center. Donna E. Shalala, PhD Michael Zigmond, PhD Page 37 Photo by John Earle courtesy of * Executive Committee Alnylam Pharmaceuticals, Inc.

MJFF ANNUAL REPORT 4

Church Street Station P.O. Box 780 New York, NY 10008-0780 (800) 708-7644 www.michaeljfox.org